{"gene":"RARB","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1990,"finding":"Recombinant RARβ (full-length and ligand-binding domain expressed in COS1 cells and E. coli) binds retinoic acid with similar affinity to RARα; only retinoid analogues with an acidic end-group actively bind both receptors; two retinoid analogues showed preferential binding to either RARα or RARβ, demonstrating that RARβ has a distinct ligand-binding site.","method":"Radioligand binding assay using recombinant full-length receptors (COS1 expression) and bacterially expressed ligand-binding domains","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro binding assay with both full-length and truncated recombinant proteins, two expression systems, replicated across multiple ligands","pmids":["2176462"],"is_preprint":false},{"year":1991,"finding":"The RARβ2 promoter contains a retinoic acid response element (RARE) that drives spatially and temporally restricted expression during mouse embryogenesis; promoter activity is selectively induced by teratogenic doses of RA in regions where malformations subsequently appear (craniofacial region, hindbrain, limbs), suggesting RARβ2 mediates some teratogenic effects of RA.","method":"Transgenic mice carrying RAR-β2 promoter–lacZ reporter gene; β-galactosidase expression mapping throughout embryogenesis; RA teratogen treatment in vivo","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple independent transgenic lines, in vivo reporter assay with RA treatment, replicated spatial pattern","pmids":["1668276"],"is_preprint":false},{"year":1992,"finding":"RARβ4, an isoform generated from the same retinoic acid-responsive P2 promoter as RARβ2 by alternative splicing, is initiated by a non-AUG (CUG) codon, has a very short A region (4 amino acids), exhibits a tissue-specific expression pattern, and has distinct transcriptional activation properties compared to other RARβ isoforms.","method":"cDNA cloning, sequencing, Northern blot for tissue expression, transient transfection transcriptional activation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — molecular cloning with sequencing, functional transcriptional assays, tissue expression characterization","pmids":["1313565"],"is_preprint":false},{"year":1994,"finding":"RARβ1/β3 transcripts are selectively expressed in embryonic CNS and their RA-induced accumulation occurs via a RA-dependent release of a block in RNA chain elongation (not transcriptional initiation), as distinct from RARβ2/β4 which are regulated at the level of transcriptional initiation via RARE.","method":"P1 promoter isolation, transgenic reporter animals, nuclear run-on transcription analysis in embryonal carcinoma cells","journal":"Mechanisms of development","confidence":"High","confidence_rationale":"Tier 1 / Strong — nuclear run-on assay directly measuring transcriptional elongation vs. initiation; validated in vivo with transgenic reporters","pmids":["8011555"],"is_preprint":false},{"year":1994,"finding":"RAR-β2 null mutant mice (targeted disruption) appear phenotypically normal, indicating other RARs compensate for RARβ2 during prenatal and postnatal development; challenging RARβ2-null embryos with teratogenic RA doses addressed whether RARβ2 is required for RA-induced malformations.","method":"Targeted gene disruption (knock-out mice), phenotypic and histological analysis, RA teratogen challenge","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with detailed phenotyping and RA challenge, published by Chambon lab","pmids":["7958449"],"is_preprint":false},{"year":1995,"finding":"Overexpression of RARβ2 in RAR-γ-null F9 cells only poorly restores differentiation (though it can replace RARγ for activation of some target genes), revealing partial functional redundancy among RARs with isoform-specific limits.","method":"Stable transfection rescue cell lines in RAR-γ-null F9 embryonal carcinoma cells; gene expression and differentiation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — rescue experiment in null background, single lab, multiple target-gene readouts","pmids":["7644503"],"is_preprint":false},{"year":1995,"finding":"Adenovirus E1A functions as a cofactor for RARβ by direct physical interaction: E1A interacts specifically with the hormone-dependent activation function (AF-2) of RARβ (but not AF-1 or AF-2 of RXRα), requiring conserved region III (CRIII) and the region around amino acid 178, thereby stabilizing the preinitiation complex and enabling RA-induced RARβ2 promoter activation.","method":"Co-immunoprecipitation, deletion mutagenesis of E1A, transient transfection transcriptional assays, GST pulldown","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding demonstrated with pulldown and Co-IP, deletion mapping of interacting domains, functional transcription assays confirming mechanistic role","pmids":["7565739"],"is_preprint":false},{"year":1996,"finding":"RARβ2 inhibits cell proliferation and anchorage-independent growth in HeLa cells: stable expression of RARβ2 results in >50% growth inhibition and reduced soft-agar colony formation, effects further enhanced by exogenous all-trans-retinoic acid.","method":"Stable transfection of RARβ2 in HeLa cells; cell proliferation assays; soft agar colony formation assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cellular phenotype with loss/gain of function, two orthogonal proliferation readouts, single lab","pmids":["8635481"],"is_preprint":false},{"year":1996,"finding":"Translation of RARβ2 mRNA is regulated by upstream open reading frames (uORFs) in the 5'-UTR; uORF4 encodes a peptide whose amino acid sequence (not merely the act of translation) is critical for inhibiting translation of the downstream major ORF in heart and brain, while uORFs 2 and 5 are important for efficient translation in all tissues.","method":"Systematic site-directed mutagenesis of uORF start codons and coding sequences; transient expression with reporter constructs in multiple tissues","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis distinguishing peptide sequence vs. translational reinitiation, tested in multiple tissue contexts","pmids":["8769409"],"is_preprint":false},{"year":1997,"finding":"Homozygous RARβ null mice are growth-deficient and display homeotic transformations of cervical vertebrae, a retrolenticular membrane, and persistence/hyperplasia of the primary vitreous body; RARα/RARβ double mutants have severe visceral abnormalities including agenesis of the stapedial artery, thymic and spleen agenesis, and abnormal inferior vena cava; RARβ/RARγ double mutants show major ocular defects including shortened ventral retina and prenatal retinal dysplasia.","method":"Homozygous and compound RAR knockout mouse phenotyping; histological and morphological analysis","journal":"The International journal of developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via compound knockout animals, comprehensive phenotypic analysis across multiple organ systems, replicated across labs","pmids":["9240560"],"is_preprint":false},{"year":1998,"finding":"Stable expression of RARβ in RARβ-negative, trans-RA-resistant lung cancer cells (SK-MES-1 and H661) restores trans-RA-induced growth inhibition and apoptosis (at low serum concentration), demonstrating that RARβ expression is required for retinoid responsiveness in lung cancer cells.","method":"Stable transfection of RARβ in RARβ-negative lung cancer lines; cell growth assay; fluorescence microscopy and TdT apoptosis assay","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with specific phenotypic readout (growth inhibition and apoptosis), single lab, two orthogonal assays","pmids":["9426695"],"is_preprint":false},{"year":1999,"finding":"Targeted disruption of both alleles of RARβ2 in F9 teratocarcinoma cells abolishes RA-induced growth arrest and impairs late differentiation responses (e.g., no induction of laminin B1), while early RA-responsive gene induction is markedly reduced; RA metabolism after differentiation is not impaired.","method":"Homologous recombination to generate RARβ2+/- and RARβ2-/- F9 cell lines; growth assays, morphological analysis, gene expression (early and late RA-responsive genes), RA metabolism assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — homologous recombination knockout in cell line with multiple orthogonal functional readouts, heterozygote controls, single rigorous study","pmids":["10480883"],"is_preprint":false},{"year":1999,"finding":"RARβ mediates the response of Hoxd4 and Hoxb4 to exogenous RA: Rarb-null mice show only partial anteriorization of Hoxd4 and Hoxb4 expression in response to RA treatment; genetic analysis shows no synergistic interaction between Hoxd4 and Rarb in cervical vertebrae specification.","method":"Rarb-null mice treated with RA; in situ hybridization for Hoxd4 and Hoxb4; Hoxd4/Rarb double-mutant generation","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in knockout mice, in situ hybridization, single lab","pmids":["10373014"],"is_preprint":false},{"year":2000,"finding":"RARβ2 transfection into RARβ-deficient lung tumor cells upregulates ICAM-1 and MHC class I expression (mRNA and cell surface protein), and enhances heterologous CTL responses up to threefold in both induction and effector phases, revealing a role for RARβ2 in regulating tumor cell immunogenicity.","method":"cDNA array (Atlas human cDNA array); flow cytometry for ICAM-1 and MHC class I protein; CTL response assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transfection gain-of-function with protein-level confirmation by flow cytometry and functional immune assay, single lab","pmids":["10834944"],"is_preprint":false},{"year":2002,"finding":"Nicotine abrogates the growth inhibitory effect of trans-RA by suppressing RA-induced RARβ expression; this suppression is mediated by nicotine-induced orphan receptor TR3, which interacts with COUP-TF, inhibiting COUP-TF DNA binding and transactivation on the RARβ promoter; RXR-selective retinoid SR11237 activates the RARβ promoter through RXR/TR3 heterodimer and escapes nicotine suppression.","method":"Transient transfection promoter activity assays; TR3 antisense RNA overexpression; co-transfection of TR3 expression vector; cell growth assays","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection with promoter assays, antisense RNA, and co-transfection, single lab, multiple orthogonal experiments","pmids":["11979430"],"is_preprint":false},{"year":2002,"finding":"The RA-insensitivity of RARβ induction in RA-resistant colon cancer cells (DLD-1) is associated with differential coactivator/corepressor balance: coactivators CBP and p300 upregulate RARβ RARE activity to levels seen in sensitive cells; corepressor NCoR suppresses RARE activity; HDAC inhibitor trichostatin A restores RARβ induction, implicating histone deacetylase in RARβ gene repression.","method":"Transfection of reporter constructs with RARβ promoter fragments; cotransfection of coactivators (CBP, p300) and corepressor (NCoR); Western blot for coregulator expression; HDAC inhibitor treatment","journal":"Biological & pharmaceutical bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter-reporter dissection with gain-of-function coregulator transfections and pharmacological inhibition, single lab","pmids":["12392082"],"is_preprint":false},{"year":2003,"finding":"RARβ–RXRα heterodimers bound to the DR4 element in the thrombomodulin (TM) promoter are required for TM transcription: oxidized phospholipids from ox-LDL reduce nuclear RARβ and RXRα levels and their binding to the DR4 element, thereby inhibiting TM gene transcription in endothelial cells.","method":"EMSA (electrophoretic mobility shift assay); TM promoter deletion/mutation reporter assays in HUVEC transfection; Western blot for nuclear receptor levels; mRNA half-life (actinomycin D) analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA binding assay plus promoter deletion reporter functional assays, single lab, two orthogonal approaches","pmids":["12576329"],"is_preprint":false},{"year":2003,"finding":"RARβ-selective agonist BMS453 induces fusion/hypoplasia of the first two branchial arches in cultured mouse embryos via RARβ/RXR heterodimers specifically in pharyngeal endoderm (not neural crest or ectoderm); effects are absent in Rarb-null embryos, enhanced by RXR agonists, and accompanied by ectopic RARβ target gene expression; RXR ligand-dependent activity is subordinated to RARβ in this heterodimer.","method":"Ex vivo cultured mouse embryo treatment with synthetic RAR-selective agonists/antagonists; genetic rescue using Rarb-null embryos; in situ hybridization for RARβ target genes; tissue-specific responsiveness assays","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological selectivity combined with genetic null rescue, multiple agonist/antagonist controls, tissue dissection experiments","pmids":["12668623"],"is_preprint":false},{"year":2004,"finding":"A novel RARβ isoform, RARβ5, is expressed from a distinct P3 promoter activated by all-trans-RA; RARβ5 protein lacks the A, B, and part of C domains of RARβ2 (translation begins at an internal methionine); it is preferentially expressed in ER-negative breast cancer cells and may confer relative retinoid resistance.","method":"cDNA cloning and sequencing; promoter mapping; RT-PCR and Western blot across breast cancer cell lines; RA/retinoid treatment transcriptional assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — molecular characterization of novel isoform with sequencing and promoter mapping, Western blot, functional RA induction assay, single lab","pmids":["15604252"],"is_preprint":false},{"year":2005,"finding":"RARβ mediates retinoid-driven striatal STEP (striatal-enriched tyrosine phosphatase) expression: RARβ-null mice show reduced STEP mRNA in the striatum, and ectopic RARβ1 expression in cerebral cortex enhances STEP expression in an RARβ-isoform-specific manner.","method":"RT-PCR in RARβ-/- mice; ectopic expression of RARβ1 by in utero electroporation; in situ hybridization and quantitative gene expression","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function knockout plus gain-of-function ectopic expression, isoform specificity tested, single lab","pmids":["15736225"],"is_preprint":false},{"year":2007,"finding":"At the RARβ2 RARE in F9 cells, RARγ and RXRα are constitutively bound; upon RA treatment, coactivators pCIP, p300, and RNA Pol II levels increase at the RARβ2 RARE; the polycomb protein SUZ12 is associated with the RARβ2 RARE and is evicted upon RA treatment (and reassociates upon RA removal); bivalent H3K4me2/H3K27me3 chromatin marks coexist at target loci, with H3K27me3 decreasing during RA-mediated differentiation.","method":"Chromatin immunoprecipitation (ChIP) for RARγ, RXRα, pCIP, p300, RNA Pol II, SUZ12, and histone marks in F9 cells ± RA treatment","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP assays for multiple factors and histone marks at defined genomic loci, dynamic RA-dependent kinetics, rigorous controls","pmids":["17663992"],"is_preprint":false},{"year":2008,"finding":"Rexinoid-induced IGFBP-6 expression requires RARβ-dependent cooperation between retinoid receptors and AP-1: a classical RARE in IGFBP-6 intron 1 adjacent to an AP-1 site is essential; bexarotene increases occupancy of this element by RXRα, RARβ, cJun, cFos, and p300; siRNA knockdown of RARβ (but not RARα or RARγ alone) blocks IGFBP-6 induction and prevents RXRα and cJun recruitment to the enhancer.","method":"Chromatin immunoprecipitation; siRNA knockdown of individual RAR/RXR isoforms; IGFBP-6 reporter assays; Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP plus isoform-specific siRNA knockdown plus reporter assays identifying both cis-elements and trans-factors, single rigorous study with multiple orthogonal methods","pmids":["18957410"],"is_preprint":false},{"year":2008,"finding":"RARβ activation stimulates Sonic hedgehog (Shh) signaling and induces proliferation of adult forebrain neural progenitor cells (NPCs); subsequent RARα signaling drives differentiation into Doublecortin-expressing migrating neuroblasts and cholinergic neurons; FGF signaling induces CYP26A1 expression and its product 4-oxo-RA mimics RARα agonist action in neuronal differentiation.","method":"In vivo and in vitro RARβ/RARα agonist treatment of adult forebrain NPCs; immunostaining for GFAP, DCX, cholinergic markers; pharmacological pathway dissection (Shh inhibitors, FGF treatment)","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with specific agonists, immunostaining cellular readouts, single lab","pmids":["19100254"],"is_preprint":false},{"year":2011,"finding":"RA-RARβ transcriptionally represses Lingo-1 (a component of the NgR inhibitory complex), thereby counteracting myelin-dependent inhibition of neurite outgrowth; suppression of Lingo-1 is required for RARβ-mediated promotion of neurite outgrowth; in vivo RA treatment after dorsal column injury inhibits Lingo-1 expression specifically through RARβ.","method":"In vitro neurite outgrowth assays with RA/RARβ agonists on myelin substrates; Lingo-1 siRNA knockdown rescue; in vivo dorsal column overhemisection model with RA treatment; RARβ-null genetic controls","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function (Lingo-1 siRNA), pharmacological, and genetic (RARβ-null) evidence converging on a defined mechanism, in vitro and in vivo","pmids":["21690307"],"is_preprint":false},{"year":2013,"finding":"RARβ regulates p14ARF levels in human melanocytes: ATRA treatment increases p14ARF expression via RARβ; an inverse correlation exists between RARB promoter hypermethylation and p14ARF (CDKN2A) alterations in melanoma cell lines; ATRA-induced senescence is reduced in p14ARF-depleted melanocytes, establishing a RARβ–p14ARF signaling axis.","method":"Mutual exclusivity analysis in 110 melanoma cell lines; ATRA treatment of primary melanocytes with p14ARF measurement; siRNA depletion of p14ARF; senescence assays","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — combination of correlational genomics with functional siRNA knockdown and pharmacological intervention, single lab","pmids":["23851445"],"is_preprint":false},{"year":2013,"finding":"TLR3 activation by polyinosinic:polycytidylic acid induces microRNAs (miR-29b, -29c, -148b, -152) that target DNA methyltransferases, leading to demethylation and re-expression of epigenetically silenced RARβ; re-expressed RARβ renders prostate and breast cancer cells sensitive to retinoic acid-induced apoptosis in vitro and in vivo.","method":"miRNA expression profiling; luciferase reporter assays for miRNA-DNMT targeting; methylation-specific PCR for RARβ demethylation; apoptosis assays in vitro; in vivo tumor xenograft models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway from TLR3 → miRNAs → DNMT → RARβ demethylation established with multiple assays and in vivo validation, single lab","pmids":["23716670"],"is_preprint":false},{"year":2013,"finding":"RARβ activation by a specific agonist in neurons decreases PTEN activity by cytoplasmic phosphorylation and increases PTEN secretion in exosomes; these PTEN-containing exosomes are taken up by astrocytes, hampering their proliferation and preventing glial scar formation; this dual mechanism results in axonal regeneration after dorsal root neurotmesis.","method":"RARβ agonist treatment in rat cervical avulsion model; BDA axonal tracing; exosome inhibitor in vivo and PTEN siRNA in vitro; phospho-PTEN Western blot; astrocyte proliferation assays","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection with pharmacological, siRNA, and exosome-inhibitor approaches, in vitro and in vivo, single lab","pmids":["26609164"],"is_preprint":false},{"year":2013,"finding":"RARβ deletion impairs pancreatic endocrine differentiation: RARβ knockout embryonic stem cells show greatly reduced expression of glucagon, IAPP, and Ins1 during directed differentiation into pancreatic islet cells.","method":"RARβ knockout ES cell differentiation protocol; RT-PCR for endocrine markers","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined differentiation protocol and specific marker readouts, single lab","pmids":["23756134"],"is_preprint":false},{"year":2015,"finding":"NR2F1-induced dormancy in disseminated tumor cells requires RARβ: NR2F1-dependent quiescence is dependent on SOX9, RARβ, and CDK inhibitors; this dormancy programme is recapitulated by co-treatment with 5-Aza-C and retinoic acid.","method":"shRNA knockdown of RARβ/SOX9 in experimental dormancy models; in vivo HNSCC and prostate cancer dormancy assays; flow cytometry for cell cycle arrest","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function knockdown in dormancy models in vitro and in vivo, epistasis placing RARβ downstream of NR2F1, single lab","pmids":["25636082"],"is_preprint":false},{"year":2015,"finding":"RARβ activates CD38 transcription in hypothalamic neurons: ChIP assays show RA enhances binding of RARβ to the proximal promoter of CD38; adenoviral RARβ overexpression or siRNA knockdown bidirectionally modulates CD38 levels; RARβ activation increases neuronal Ca2+ excitability and OXT release; gestational vitamin A deficiency reduces hypothalamic RARβ and CD38, impairing oxytocin signaling.","method":"Chromatin immunoprecipitation (ChIP); adenoviral RARβ overexpression and siRNA knockdown in primary hypothalamic neurons; Ca2+ imaging; serum oxytocin ELISA; rat gestational VAD model","journal":"Molecular nutrition & food research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — ChIP directly showing RARβ binding to CD38 promoter, bidirectional gain/loss of function, in vitro and in vivo, single lab","pmids":["29266770"],"is_preprint":false},{"year":2016,"finding":"De novo gain-of-function mutations in RARB (p.Gly296Ala and p.Leu213Pro) increase RA ligand-induced transcriptional activity 2- to 3-fold over wild-type receptor in transfection assays, consistent with previously reported p.Arg387Cys/Ser mutations; these mutations cause a syndrome of microphthalmia, diaphragmatic hernia, global developmental delay, and progressive motor impairment.","method":"Transient transfection transcriptional activation assays comparing wild-type vs. mutant RARB; clinical characterization of patients with de novo mutations","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct functional transcriptional assay with mutant constructs demonstrating gain-of-function, single lab","pmids":["27120018"],"is_preprint":false},{"year":2016,"finding":"Genome-wide ChIP-seq of RARβ in mouse striatum combined with transcriptomics of RARβ-null mice identifies RARβ transcriptional targets enriched for neurotransmission, energy metabolism, and G-protein coupled receptor signaling (including cAMP and calcium pathways); RARβ is partially sequestered in huntingtin protein aggregates in R6/2 HD mice, reducing RA signaling in HD.","method":"ChIP-seq for RARβ in striatum; RNA-seq transcriptomics of RARβ-null mice; co-immunoprecipitation/immunofluorescence for RARβ-huntingtin co-localization in R6/2 mice","journal":"Molecular neurobiology","confidence":"High","confidence_rationale":"Tier 1 / Strong — genome-wide ChIP-seq plus knockout transcriptomics plus protein interaction in disease model, rigorous multi-omic approach, single lab","pmids":["27405468"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of multi-domain RARβ–RXRα heterodimer bound to DNA, ligands, and coactivator peptides reveals that the RARβ LBD and DBD are physically connected through domain-domain interactions, enabling allosteric signal transmission between them; RXR remains flexible with loosely organized domains while RARβ LBD forms direct contact with the DBD via a surface patch.","method":"X-ray crystallography; hydrogen-deuterium exchange mass spectrometry (HDX-MS); mutagenesis of domain-domain interface; functional transcriptional assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure at high resolution with HDX-MS allosteric evidence and mutagenesis validation in a single rigorous study","pmids":["29021580"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of the RARβ LBD in complex with the RARβ-selective full agonist BMS948 and related compounds BMS641 and BMS411 reveals that a 180° flip of the amide linker accounts for RARβ selectivity over RARα; this structural analysis explains how a single retinoid can be an RARα antagonist and an RARβ full agonist simultaneously, and defines structural basis of partial agonism.","method":"X-ray crystallography of RARβ LBD–ligand complexes; transcriptional activation assays for agonist/antagonist properties","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures of RARβ LBD with multiple ligands, functional assays confirming agonist/antagonist properties","pmids":["25933005"],"is_preprint":false},{"year":2018,"finding":"TBL1XR1-RARB fusion protein (from translocation in RARA-negative APL) homodimerizes and acts as a dominant-negative repressor of the retinoic acid receptor pathway; it enhances replating capacity of mouse bone marrow cells and inhibits myeloid maturation of human cord blood cells, similarly to PML-RARA; APL with RARB translocation shows attenuated response to ATRA.","method":"Whole-genome sequencing; PCR and FISH for translocations; transduction of TBL1XR1-RARB into cell lines; reporter assays for RA pathway transcriptional activity; bone marrow replating assay; cord blood myeloid differentiation assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Strong — molecular characterization of fusion protein, in vitro functional assays (dimerization, transcription, differentiation), and in vivo bone marrow assay in single rigorous study","pmids":["29921692"],"is_preprint":false},{"year":2018,"finding":"RARβ acts as both an upstream regulator and downstream effector of miR-22 in colon cancer cells: RA and HDAC inhibitors induce miR-22 via RARβ binding to a DR5 motif; miR-22 in turn reduces HDAC1, HDAC4, and SIRT1 (through chromatin remodeling of RARβ and NUR77 loci); this circuit leads to simultaneous induction of cytoplasmic RARβ and NUR77, causing apoptosis.","method":"ChIP for RARβ binding to DR5 at miR-22 locus; miR-22 target validation (HDAC1); luciferase reporter assays; Western blot for RARβ/NUR77/HDACs; xenograft tumor model with miR-22 inducers","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishing direct RARβ binding to DR5, functional circuit validation with multiple assays and in vivo model, single lab","pmids":["30252536"],"is_preprint":false},{"year":2018,"finding":"Combinatorial CRISPR knockout of all three RARs (α, β, γ) in murine embryonic stem cells completely abrogates all transcriptional responses to RA, demonstrating that RARs are essential for every RA-regulated transcript; no RAR-independent RA signaling pathway operates in these cells.","method":"CRISPR-mediated biallelic frameshift mutations in RARα, RARβ, and RARγ; RNA-seq transcriptome analysis of triple-null vs. WT cells ± RA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — genome-scale genetic proof using triple CRISPR knockout and RNA-seq, comprehensive and definitive single-study design","pmids":["29848550"],"is_preprint":false},{"year":2019,"finding":"CCL28 signaling via CCR10 increases RARβ expression by reducing the interaction between RARα and HDAC1; elevated RARβ inhibits invasion, EMT (inducing E-cadherin, reducing nuclear β-catenin), and RANKL-driven osteoclastogenesis in oral squamous cell carcinoma; intraperitoneally administered CCL28 inhibits tumor growth and osteolysis in mouse models.","method":"Co-immunoprecipitation of RARα–HDAC1 interaction ± CCL28; Western blot and invasion assays; mouse calvaria and tibia OSCC models; IHC of tumor tissues for RARβ","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing mechanism of RARβ upregulation, in vitro functional assays, in vivo xenograft model, single lab","pmids":["31487270"],"is_preprint":false},{"year":2019,"finding":"RARβ (NR1B2) overexpression inhibits and knockdown promotes KIRC cell invasion and metastasis in vitro and in vivo; mechanistic investigation indicates RARβ suppresses EMT through the LATS1/2-YAP pathway.","method":"Lentiviral stable overexpression and knockdown of NR1B2 in KIRC cell lines; migration/invasion assays; nude mouse xenograft metastasis model; Western blot for EMT markers and LATS1/2-YAP pathway components","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional loss/gain of function in vitro and in vivo with defined pathway readout (LATS1/2-YAP), single lab","pmids":["31391070"],"is_preprint":false},{"year":2023,"finding":"RARβ mediates RA protection against LPS-induced ferroptosis in hepatocytes: knockdown of RARβ gene significantly diminishes RA's anti-ferroptotic protective effect; RAR agonist/antagonist experiments show RARβ (and RARγ) activation is required for RA inhibition of ferroptosis; the mechanism involves regulation of Nrf2/HO-1/GPX4 signaling.","method":"RARβ gene knockdown in hepatocytes; RAR subtype-selective agonists and antagonists; LPS/erastin/RSL3-induced ferroptosis models; Western blot for Nrf2/HO-1/GPX4; serum iron and RBC disorder measurements in mice","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with selective agonist/antagonist pharmacology, in vitro and in vivo, single lab","pmids":["37302616"],"is_preprint":false}],"current_model":"RARβ is a ligand-activated nuclear receptor that forms heterodimers with RXRα (and heterodimerizes with TBL1XR1 as an oncogenic fusion) whose crystal structure reveals allosteric domain-domain communication between the LBD and DBD; it binds retinoic acid and selective synthetic agonists (e.g., BMS948) to drive transcription of target genes (including RARβ2 itself, CD38, IGFBP-6, and Hox genes) via RAREs, with transcriptional output modulated by coactivators (CBP/p300/pCIP), corepressors (NCoR/HDAC1/EZH2/SUZ12), upstream open reading frames that regulate translation, and post-transcriptional silencing by miR-146 and miR-106a; functionally, RARβ2 is required for RA-induced growth arrest, promotes apoptosis and tumor cell immunogenicity, represses Lingo-1 to enable axonal regeneration, activates Shh signaling in neural progenitor proliferation, regulates PTEN activity and exosomal transfer to prevent glial scarring, drives the RARβ–p14ARF axis to suppress melanoma, and controls pancreatic endocrine differentiation and CD38-oxytocin signaling in the hypothalamus, while gain-of-function mutations cause a neurodevelopmental syndrome and dominant-negative RARB fusions drive retinoic acid-resistant acute promyelocytic leukemia."},"narrative":{"mechanistic_narrative":"RARβ is a ligand-activated nuclear receptor that binds retinoic acid through a distinct ligand-binding site and functions as the obligatory transcriptional effector of retinoid signaling, where combinatorial CRISPR knockout of all three RARs abolishes every RA-regulated transcript [PMID:2176462, PMID:29848550]. It operates as a RARβ–RXRα heterodimer bound to retinoic acid response elements; a multi-domain crystal structure of the DNA-bound heterodimer shows the RARβ ligand-binding domain physically contacts the DNA-binding domain to relay allosteric signals, while companion structures with the selective agonist BMS948 explain RARβ-selective activation through a flip of the amide linker [PMID:29021580, PMID:25933005]. Transcription from the RA-responsive RARβ2 (P2) promoter is governed by a RARE and tuned by the coactivator/corepressor balance — CBP, p300, and pCIP promote activity while NCoR, HDAC1, and the polycomb factor SUZ12 with bivalent H3K27me3 chromatin enforce repression — and the receptor itself drives target genes including IGFBP-6, CD38, Hox genes, and STEP [PMID:12392082, PMID:17663992, PMID:18957410, PMID:29266770]. RARβ output is further layered by additional isoforms from distinct promoters (β2/β4 via P2, β1/β3 via P1 elongation control, β5 via P3) and by uORF-mediated translational control of its 5'-UTR [PMID:1313565, PMID:8011555, PMID:8769409, PMID:15604252]. Functionally, RARβ2 is required for RA-induced growth arrest and apoptosis and confers retinoid responsiveness in cancer cells [PMID:9426695, PMID:10480883], suppresses tumorigenesis via a RARβ–p14ARF senescence axis and restraint of EMT [PMID:23851445, PMID:31391070], enhances tumor immunogenicity [PMID:10834944], and in the nervous system represses Lingo-1 to enable neurite outgrowth, modulates PTEN secretion to prevent glial scarring, and stimulates Shh-dependent neural progenitor proliferation [PMID:19100254, PMID:21690307, PMID:26609164]. In vivo, RARβ-null mice show homeotic vertebral transformations and ocular defects with extensive redundancy among RARs [PMID:9240560]. Gain-of-function de novo RARB mutations that increase ligand-induced transcriptional activity cause a syndrome of microphthalmia, diaphragmatic hernia, and developmental delay [PMID:27120018], while a dominant-negative TBL1XR1-RARB fusion drives retinoic acid-resistant acute promyelocytic leukemia [PMID:29921692].","teleology":[{"year":1990,"claim":"Established that RARβ is a genuine retinoic acid receptor with a ligand-binding site distinct from RARα, providing the basis for subtype-selective retinoid pharmacology.","evidence":"Radioligand binding with recombinant full-length receptors and bacterially expressed LBDs across multiple retinoid analogues","pmids":["2176462"],"confidence":"High","gaps":["Did not define the structural determinants of subtype selectivity","No information on heterodimer requirement for binding in vivo"]},{"year":1991,"claim":"Showed the RARβ2 promoter carries a functional RARE driving spatially restricted RA-responsive expression in the embryo, linking RARβ to RA teratogenesis.","evidence":"Transgenic RARβ2 promoter–lacZ reporter mice with in vivo RA challenge","pmids":["1668276"],"confidence":"High","gaps":["Correlative for teratogenic causation rather than proof","Did not identify downstream effector genes"]},{"year":1994,"claim":"Distinguished how RARβ isoforms are differentially regulated — β2/β4 at transcriptional initiation via RARE versus β1/β3 via release of an elongation block — revealing layered control of receptor abundance.","evidence":"P1/P2 promoter analysis, transgenic reporters, and nuclear run-on assays in embryonal carcinoma cells; isoform cloning","pmids":["8011555","1313565"],"confidence":"High","gaps":["Factors controlling the elongation block not identified","Physiological role of isoform diversity unresolved"]},{"year":1994,"claim":"Genetic knockout demonstrated extensive functional redundancy among RARs, showing single RARβ loss is largely compensated in development.","evidence":"Targeted disruption of RARβ in mice with phenotyping and RA teratogen challenge","pmids":["7958449"],"confidence":"High","gaps":["Did not resolve which RARs compensate at specific loci","Subtle or adult phenotypes not fully captured"]},{"year":1995,"claim":"Defined isoform-specific limits to RAR redundancy, as RARβ2 only poorly rescues differentiation in RARγ-null cells.","evidence":"Stable rescue transfection in RARγ-null F9 embryonal carcinoma cells with differentiation readouts","pmids":["7644503"],"confidence":"Medium","gaps":["Single cell-line context","Mechanistic basis of isoform specificity not defined"]},{"year":1995,"claim":"Identified E1A as a direct AF-2-interacting cofactor of RARβ, providing early mechanistic detail on coactivator-like stabilization of the RARβ preinitiation complex.","evidence":"Co-IP, GST pulldown, E1A deletion mapping, and transcriptional reporter assays","pmids":["7565739"],"confidence":"High","gaps":["Viral cofactor; endogenous equivalent not established here","Structural basis of AF-2 contact undefined at the time"]},{"year":1996,"claim":"Linked RARβ2 expression to tumor suppression by showing it inhibits proliferation and anchorage-independent growth, and uncovered uORF-based translational regulation of the receptor.","evidence":"Stable RARβ2 expression in HeLa with proliferation/soft-agar assays; systematic uORF mutagenesis with reporters across tissues","pmids":["8635481","8769409"],"confidence":"High","gaps":["Growth-arrest target genes not identified in these studies","uORF regulation not tied to disease phenotypes"]},{"year":1998,"claim":"Demonstrated that RARβ expression is required and sufficient to restore retinoid-induced growth inhibition and apoptosis in RA-resistant lung cancer cells, establishing RARβ loss as a mechanism of retinoid resistance.","evidence":"Stable RARβ transfection in RARβ-negative lung cancer lines with growth and TdT apoptosis assays","pmids":["9426695"],"confidence":"Medium","gaps":["Apoptotic effector pathway not mapped","Single lab, limited cell lines"]},{"year":1999,"claim":"Cell-line knockout and mouse genetics defined RARβ2 as required for RA-induced growth arrest and late differentiation, and as the mediator of RA-dependent Hox anteriorization.","evidence":"Biallelic RARβ2 disruption in F9 cells with growth/differentiation readouts; Rarb-null mice with Hoxd4/Hoxb4 in situ hybridization","pmids":["10480883","10373014"],"confidence":"Medium","gaps":["Only partial Hox responses, indicating additional receptors","Direct vs. indirect target distinction incomplete"]},{"year":1997,"claim":"Compound RAR knockouts revealed genetic epistasis and organ-specific requirements (vertebral homeosis, ocular development) for RARβ in concert with RARα and RARγ.","evidence":"Single and compound RAR knockout mouse phenotyping with histology","pmids":["9240560"],"confidence":"High","gaps":["Molecular targets underlying each defect not resolved","Combinatorial logic among RARs incompletely mapped"]},{"year":2002,"claim":"Defined the coregulator basis of RARβ retinoid resistance — coactivator/corepressor balance and HDAC activity control RARβ promoter induction.","evidence":"Promoter-reporter assays with CBP/p300/NCoR cotransfection and TSA HDAC inhibition in colon cancer cells; TR3/COUP-TF dissection in lung cells","pmids":["12392082","11979430"],"confidence":"Medium","gaps":["Endogenous occupancy not shown in these reporter studies","Single lab per finding"]},{"year":2007,"claim":"ChIP at the RARβ2 RARE established the dynamic chromatin logic — constitutive RAR/RXR binding, RA-induced coactivator/Pol II recruitment, SUZ12 eviction, and resolution of bivalent histone marks.","evidence":"ChIP for RARγ, RXRα, pCIP, p300, Pol II, SUZ12 and histone marks in F9 cells ± RA","pmids":["17663992"],"confidence":"High","gaps":["RARβ self-occupancy versus RARγ at the locus not fully separated","Kinetics of polycomb reassembly only partially defined"]},{"year":2008,"claim":"Identified specific RARβ target genes and cofactor cooperativity, with RARβ uniquely required for rexinoid-induced IGFBP-6 via RARE–AP-1 crosstalk.","evidence":"ChIP, isoform-specific siRNA, and reporter assays mapping cis-elements and trans-factors (RXRα, cJun, cFos, p300)","pmids":["18957410"],"confidence":"High","gaps":["Generalizability of RARE–AP-1 cooperation to other targets unknown","Single cell context"]},{"year":2003,"claim":"Showed RARβ–RXR heterodimers act in defined tissues to control target gene expression in vivo and bind functional DR-type elements regulating non-developmental genes such as thrombomodulin.","evidence":"Ex vivo embryo culture with RARβ-selective agonists and Rarb-null rescue; EMSA and promoter reporters at the thrombomodulin DR4 in endothelial cells","pmids":["12668623","12576329"],"confidence":"High","gaps":["Direct RARβ occupancy at endogenous TM promoter not shown by ChIP","Tissue-specific cofactor requirements unmapped"]},{"year":2013,"claim":"Expanded RARβ tumor-suppressive mechanisms — a RARβ–p14ARF senescence axis, RARβ re-expression upon DNMT-targeting miRNAs restoring RA-induced apoptosis, and roles in immunogenicity, dormancy, and endocrine/neuronal differentiation.","evidence":"ATRA/siRNA p14ARF senescence assays in melanocytes; TLR3→miRNA→DNMT→RARβ demethylation with xenografts; NR2F1 dormancy knockdown; cDNA array/flow CTL assays; ES-cell pancreatic differentiation","pmids":["23851445","23716670","25636082","10834944","23756134"],"confidence":"Medium","gaps":["Many findings are single-lab and context-specific","Direct RARβ target genes in these settings not always defined"]},{"year":2011,"claim":"Established RARβ as a driver of CNS repair by transcriptionally repressing Lingo-1, decreasing PTEN activity/exosomal export, and promoting Shh-dependent neural progenitor proliferation.","evidence":"Neurite outgrowth assays, Lingo-1 siRNA rescue, dorsal column injury and avulsion models with RARβ-null controls, exosome inhibition, pharmacological pathway dissection","pmids":["21690307","19100254","26609164"],"confidence":"Medium","gaps":["Whether Lingo-1 and PTEN are direct RARβ targets not fully resolved","Translation to therapeutic settings untested in these studies"]},{"year":2015,"claim":"Solved the structural basis of RARβ subtype-selective ligand recognition, explaining how single compounds act as RARβ agonists while antagonizing RARα.","evidence":"X-ray crystallography of RARβ LBD with BMS948/BMS641/BMS411 plus transcriptional assays","pmids":["25933005"],"confidence":"High","gaps":["Isolated LBD; full-length context addressed separately","In vivo selectivity consequences not tested here"]},{"year":2016,"claim":"Defined RARβ's genome-wide neuronal target program and a CD38–oxytocin regulatory pathway, and linked RARβ sequestration in huntingtin aggregates to impaired RA signaling in disease.","evidence":"ChIP-seq of striatal RARβ with RARβ-null RNA-seq; ChIP and bidirectional manipulation at the CD38 promoter with Ca2+ imaging and oxytocin ELISA; Co-IP/IF in R6/2 HD mice","pmids":["27405468","29266770"],"confidence":"High","gaps":["Functional validation of most genome-wide targets pending","Causal contribution of RARβ sequestration to HD phenotype not isolated"]},{"year":2016,"claim":"Established that gain-of-function RARB mutations causing increased ligand-induced transcription underlie a defined neurodevelopmental syndrome, providing direct human disease evidence.","evidence":"Transcriptional activation assays of mutant versus wild-type RARB with clinical characterization of de novo mutation carriers","pmids":["27120018"],"confidence":"Medium","gaps":["Tissue-specific consequences of hyperactivity not modeled","Genotype–phenotype mapping limited to a few mutations"]},{"year":2017,"claim":"Revealed the integrated architecture of the DNA-bound RARβ–RXRα heterodimer, showing LBD–DBD allosteric coupling that links ligand binding to DNA engagement.","evidence":"Multi-domain X-ray crystallography with HDX-MS, interface mutagenesis, and transcriptional assays","pmids":["29021580"],"confidence":"High","gaps":["Dynamics in the presence of full coactivator complexes not captured","Chromatin context not represented in the crystal"]},{"year":2018,"claim":"Provided definitive genetic proof that RARs (including RARβ) are obligatory for all RA transcriptional responses, and identified a dominant-negative TBL1XR1-RARB fusion driving RA-resistant APL.","evidence":"Triple RAR CRISPR knockout with RNA-seq; characterization of TBL1XR1-RARB dimerization, transcriptional repression, replating, and differentiation assays","pmids":["29848550","29921692"],"confidence":"High","gaps":["Triple-null result is in ES cells; tissue generalization assumed","Fusion partner contribution to oncogenicity not fully dissected"]},{"year":2019,"claim":"Extended RARβ's anti-tumor role to invasion/EMT control via LATS1/2-YAP and CCL28/CCR10-driven RARβ upregulation, and to metabolic/redox protection against ferroptosis.","evidence":"Bidirectional NR1B2 manipulation with LATS1/2-YAP readouts in KIRC; RARα–HDAC1 Co-IP and OSCC models; RARβ knockdown with agonist/antagonist ferroptosis assays and Nrf2/HO-1/GPX4 analysis","pmids":["31391070","31487270","37302616"],"confidence":"Medium","gaps":["Direct RARβ transcriptional targets in these pathways not mapped","Single-lab, context-specific findings"]},{"year":null,"claim":"How RARβ's diverse target programs and tissue-specific cofactor/chromatin states are selected across contexts — and how gain-of-function and dominant-negative alleles produce their specific disease phenotypes mechanistically — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking isoform/promoter usage to context-specific output","Mechanistic basis of mutant phenotypes at the tissue level undefined","Direct versus indirect status of many proposed targets unconfirmed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[20,21,29,31,36]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[16,21,32]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[0,33]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[16,20,32]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[20,21,29,36]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9,17,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[30,34]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,11,35]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[20]}],"complexes":["RARβ–RXRα heterodimer"],"partners":["RXRA","NCOR1","CREBBP","EP300","SUZ12","TBL1XR1","HTT","HDAC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P10826","full_name":"Retinoic acid receptor beta","aliases":["HBV-activated protein","Nuclear receptor subfamily 1 group B member 2","RAR-epsilon"],"length_aa":455,"mass_kda":50.5,"function":"Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors (PubMed:12554770). The RXRA/RARB heterodimer can act as a repressor on the DR1 element and as an activator on the DR5 element (PubMed:29021580). In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P10826/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RARB","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RARB","total_profiled":1310},"omim":[{"mim_id":"615524","title":"MICROPHTHALMIA, SYNDROMIC 12; MCOPS12","url":"https://www.omim.org/entry/615524"},{"mim_id":"608317","title":"GRAINYHEAD-LIKE 3; GRHL3","url":"https://www.omim.org/entry/608317"},{"mim_id":"606083","title":"POLYBROMO 1; PBRM1","url":"https://www.omim.org/entry/606083"},{"mim_id":"605522","title":"LIMB DEVELOPMENT MEMBRANE PROTEIN 1; LMBR1","url":"https://www.omim.org/entry/605522"},{"mim_id":"605226","title":"ARGININE-GLUTAMIC ACID DIPEPTIDE REPEATS; RERE","url":"https://www.omim.org/entry/605226"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RARB"},"hgnc":{"alias_symbol":["HAP","NR1B2","RRB2","RARbeta","RAR-beta"],"prev_symbol":[]},"alphafold":{"accession":"P10826","domains":[{"cath_id":"3.30.50.10","chopping":"98-158","consensus_level":"high","plddt":96.7428,"start":98,"end":158},{"cath_id":"1.10.565.10","chopping":"183-415","consensus_level":"high","plddt":96.283,"start":183,"end":415}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10826","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10826-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10826-F1-predicted_aligned_error_v6.png","plddt_mean":79.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RARB","jax_strain_url":"https://www.jax.org/strain/search?query=RARB"},"sequence":{"accession":"P10826","fasta_url":"https://rest.uniprot.org/uniprotkb/P10826.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10826/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10826"}},"corpus_meta":[{"pmid":"25636082","id":"PMC_25636082","title":"NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25636082","citation_count":299,"is_preprint":false},{"pmid":"16203797","id":"PMC_16203797","title":"Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16203797","citation_count":296,"is_preprint":false},{"pmid":"1668276","id":"PMC_1668276","title":"Developmental analysis of the retinoic acid-inducible RAR-beta 2 promoter in transgenic animals.","date":"1991","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1668276","citation_count":251,"is_preprint":false},{"pmid":"14601057","id":"PMC_14601057","title":"DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14601057","citation_count":209,"is_preprint":false},{"pmid":"9240560","id":"PMC_9240560","title":"Role of the retinoic acid receptor beta (RARbeta) during mouse development.","date":"1997","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9240560","citation_count":205,"is_preprint":false},{"pmid":"12773202","id":"PMC_12773202","title":"Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome.","date":"2003","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12773202","citation_count":179,"is_preprint":false},{"pmid":"16449996","id":"PMC_16449996","title":"Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16449996","citation_count":177,"is_preprint":false},{"pmid":"9271385","id":"PMC_9271385","title":"RRB1 and RRB2 encode maize retinoblastoma-related proteins that interact with a plant D-type cyclin and geminivirus replication protein.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9271385","citation_count":168,"is_preprint":false},{"pmid":"2176462","id":"PMC_2176462","title":"Ligand specificities of recombinant retinoic acid receptors RAR alpha and RAR beta.","date":"1990","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/2176462","citation_count":156,"is_preprint":false},{"pmid":"7958449","id":"PMC_7958449","title":"Retinoic acid receptor beta 2 (RAR beta 2) null mutant mice appear normal.","date":"1994","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7958449","citation_count":136,"is_preprint":false},{"pmid":"12839965","id":"PMC_12839965","title":"Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12839965","citation_count":132,"is_preprint":false},{"pmid":"1313565","id":"PMC_1313565","title":"RAR-beta 4, a retinoic acid receptor isoform is generated from RAR-beta 2 by alternative splicing and usage of a CUG initiator codon.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1313565","citation_count":119,"is_preprint":false},{"pmid":"17663992","id":"PMC_17663992","title":"Retinoid regulated association of transcriptional co-regulators and the polycomb group protein SUZ12 with the retinoic acid response elements of Hoxa1, RARbeta(2), and Cyp26A1 in F9 embryonal carcinoma cells.","date":"2007","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17663992","citation_count":112,"is_preprint":false},{"pmid":"10480883","id":"PMC_10480883","title":"The targeted disruption of both alleles of RARbeta(2) in F9 cells results in the loss of retinoic acid-associated growth arrest.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10480883","citation_count":105,"is_preprint":false},{"pmid":"7644503","id":"PMC_7644503","title":"Reexpression of retinoic acid receptor (RAR) gamma or overexpression of RAR alpha or RAR beta in RAR gamma-null F9 cells reveals a partial functional redundancy between the three RAR types.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7644503","citation_count":99,"is_preprint":false},{"pmid":"1665705","id":"PMC_1665705","title":"Implication of RARB in epidermoid (Squamous) lung cancer.","date":"1991","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1665705","citation_count":99,"is_preprint":false},{"pmid":"8734497","id":"PMC_8734497","title":"Compound mutants for retinoic acid receptor (RAR) beta and RAR alpha 1 reveal developmental functions for multiple RAR beta isoforms.","date":"1996","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/8734497","citation_count":93,"is_preprint":false},{"pmid":"12668623","id":"PMC_12668623","title":"Retinoic acid-induced developmental defects are mediated by RARbeta/RXR heterodimers in the pharyngeal endoderm.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12668623","citation_count":85,"is_preprint":false},{"pmid":"26609164","id":"PMC_26609164","title":"Neuronal RARβ Signaling Modulates PTEN Activity Directly in Neurons and via Exosome Transfer in Astrocytes to Prevent Glial Scar Formation and Induce Spinal Cord Regeneration.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26609164","citation_count":85,"is_preprint":false},{"pmid":"12210063","id":"PMC_12210063","title":"Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas.","date":"2002","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12210063","citation_count":83,"is_preprint":false},{"pmid":"16157195","id":"PMC_16157195","title":"Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes.","date":"2005","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16157195","citation_count":76,"is_preprint":false},{"pmid":"29021580","id":"PMC_29021580","title":"The quaternary architecture of RARβ-RXRα heterodimer facilitates domain-domain signal transmission.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29021580","citation_count":73,"is_preprint":false},{"pmid":"9426695","id":"PMC_9426695","title":"Regulation of RAR beta expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: effect on growth inhibition and apoptosis induction.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9426695","citation_count":71,"is_preprint":false},{"pmid":"25981383","id":"PMC_25981383","title":"Curcumin Reactivates Silenced Tumor Suppressor Gene RARβ by Reducing DNA Methylation.","date":"2015","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/25981383","citation_count":70,"is_preprint":false},{"pmid":"8769409","id":"PMC_8769409","title":"Regulation of RAR beta 2 mRNA expression: evidence for an inhibitory peptide encoded in the 5'-untranslated region.","date":"1996","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8769409","citation_count":63,"is_preprint":false},{"pmid":"8011555","id":"PMC_8011555","title":"RAR beta isoforms: distinct transcriptional control by retinoic acid and specific spatial patterns of promoter activity during mouse embryonic development.","date":"1994","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/8011555","citation_count":61,"is_preprint":false},{"pmid":"27639645","id":"PMC_27639645","title":"Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27639645","citation_count":60,"is_preprint":false},{"pmid":"23716670","id":"PMC_23716670","title":"Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23716670","citation_count":57,"is_preprint":false},{"pmid":"7988554","id":"PMC_7988554","title":"Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4-like transgene.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7988554","citation_count":56,"is_preprint":false},{"pmid":"17998817","id":"PMC_17998817","title":"Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients.","date":"2006","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17998817","citation_count":51,"is_preprint":false},{"pmid":"14656941","id":"PMC_14656941","title":"Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis.","date":"2003","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/14656941","citation_count":51,"is_preprint":false},{"pmid":"23431043","id":"PMC_23431043","title":"The carotenoid lutein enhances matrix metalloproteinase-9 production and phagocytosis through intracellular ROS generation and ERK1/2, p38 MAPK, and RARβ activation in murine macrophages.","date":"2013","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/23431043","citation_count":49,"is_preprint":false},{"pmid":"8635481","id":"PMC_8635481","title":"RAR beta 2-mediated growth inhibition in HeLa cells.","date":"1996","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/8635481","citation_count":49,"is_preprint":false},{"pmid":"7864621","id":"PMC_7864621","title":"Efficacy of all-trans-beta-carotene, canthaxanthin, and all-trans-, 9-cis-, and 4-oxoretinoic acids in inducing differentiation of an F9 embryonal carcinoma RAR beta-lacZ reporter cell line.","date":"1995","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/7864621","citation_count":47,"is_preprint":false},{"pmid":"31487270","id":"PMC_31487270","title":"CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31487270","citation_count":46,"is_preprint":false},{"pmid":"31391070","id":"PMC_31391070","title":"NR1B2 suppress kidney renal clear cell carcinoma (KIRC) progression by regulation of LATS 1/2-YAP signaling.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31391070","citation_count":45,"is_preprint":false},{"pmid":"29266770","id":"PMC_29266770","title":"Vitamin A Deficiency Induces Autistic-Like Behaviors in Rats by Regulating the RARβ-CD38-Oxytocin Axis in the Hypothalamus.","date":"2018","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/29266770","citation_count":45,"is_preprint":false},{"pmid":"29921692","id":"PMC_29921692","title":"Recurrent RARB Translocations in Acute Promyelocytic Leukemia Lacking RARA Translocation.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29921692","citation_count":44,"is_preprint":false},{"pmid":"21147548","id":"PMC_21147548","title":"Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa.","date":"2010","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21147548","citation_count":44,"is_preprint":false},{"pmid":"27011326","id":"PMC_27011326","title":"Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27011326","citation_count":43,"is_preprint":false},{"pmid":"19809523","id":"PMC_19809523","title":"High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome.","date":"2009","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/19809523","citation_count":43,"is_preprint":false},{"pmid":"12576329","id":"PMC_12576329","title":"Oxidized phospholipids in oxidized low-density lipoprotein down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RARbeta-RXRalpha heterodimers and Sp1 and Sp3 to their binding sequences in the TM promoter.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12576329","citation_count":43,"is_preprint":false},{"pmid":"8751982","id":"PMC_8751982","title":"A limited role for retinoic acid and retinoic acid receptors RAR alpha and RAR beta in regulating keratin 19 expression and keratinization in oral and epidermal keratinocytes.","date":"1996","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8751982","citation_count":43,"is_preprint":false},{"pmid":"7565739","id":"PMC_7565739","title":"Adenovirus E1A functions as a cofactor for retinoic acid receptor beta (RAR beta) through direct interaction with RAR beta.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565739","citation_count":42,"is_preprint":false},{"pmid":"27120018","id":"PMC_27120018","title":"Gain-of-Function Mutations in RARB Cause Intellectual Disability with Progressive Motor Impairment.","date":"2016","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/27120018","citation_count":41,"is_preprint":false},{"pmid":"11979430","id":"PMC_11979430","title":"Nicotine modulates the effects of retinoids on growth inhibition and RAR beta expression in lung cancer cells.","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11979430","citation_count":41,"is_preprint":false},{"pmid":"27342319","id":"PMC_27342319","title":"miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.","date":"2016","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/27342319","citation_count":39,"is_preprint":false},{"pmid":"25805039","id":"PMC_25805039","title":"Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients.","date":"2015","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/25805039","citation_count":38,"is_preprint":false},{"pmid":"23376149","id":"PMC_23376149","title":"Methylation of the RARB gene increases prostate cancer risk in black Americans.","date":"2013","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/23376149","citation_count":36,"is_preprint":false},{"pmid":"29851970","id":"PMC_29851970","title":"Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29851970","citation_count":34,"is_preprint":false},{"pmid":"25197641","id":"PMC_25197641","title":"Methylation-associated gene silencing of RARB in areca carcinogens induced mouse oral squamous cell carcinoma.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25197641","citation_count":33,"is_preprint":false},{"pmid":"37302616","id":"PMC_37302616","title":"Retinoic acid protects against lipopolysaccharide-induced ferroptotic liver injury and iron disorders by regulating Nrf2/HO-1 and RARβ signaling.","date":"2023","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37302616","citation_count":33,"is_preprint":false},{"pmid":"27405468","id":"PMC_27405468","title":"Genome-wide Analysis of RARβ Transcriptional Targets in Mouse Striatum Links Retinoic Acid Signaling with Huntington's Disease and Other Neurodegenerative Disorders.","date":"2016","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27405468","citation_count":33,"is_preprint":false},{"pmid":"15604252","id":"PMC_15604252","title":"A novel RARbeta isoform directed by a distinct promoter P3 and mediated by retinoic acid in breast cancer cells.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15604252","citation_count":33,"is_preprint":false},{"pmid":"34927421","id":"PMC_34927421","title":"Carcinogenic Risk of 2,6-Di-tert-Butylphenol and Its Quinone Metabolite 2,6-DTBQ Through Their Interruption of RARβ: In Vivo, In Vitro, and In Silico Investigations.","date":"2021","source":"Environmental science & technology","url":"https://pubmed.ncbi.nlm.nih.gov/34927421","citation_count":32,"is_preprint":false},{"pmid":"19100254","id":"PMC_19100254","title":"Sequential RARbeta and alpha signalling in vivo can induce adult forebrain neural progenitor cells to differentiate into neurons through Shh and FGF signalling pathways.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19100254","citation_count":32,"is_preprint":false},{"pmid":"23756134","id":"PMC_23756134","title":"Deletion of retinoic acid receptor β (RARβ) impairs pancreatic endocrine differentiation.","date":"2013","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/23756134","citation_count":30,"is_preprint":false},{"pmid":"30252536","id":"PMC_30252536","title":"RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30252536","citation_count":29,"is_preprint":false},{"pmid":"33058988","id":"PMC_33058988","title":"Polymethoxyflavones from citrus inhibited gastric cancer cell proliferation through inducing apoptosis by upregulating RARβ, both in vitro and in vivo.","date":"2020","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/33058988","citation_count":29,"is_preprint":false},{"pmid":"24492483","id":"PMC_24492483","title":"Synergistic chromatin repression of the tumor suppressor gene RARB in human prostate cancers.","date":"2014","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/24492483","citation_count":26,"is_preprint":false},{"pmid":"29538221","id":"PMC_29538221","title":"Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.","date":"2018","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29538221","citation_count":25,"is_preprint":false},{"pmid":"26823825","id":"PMC_26823825","title":"DAPK1, MGMT and RARB promoter methylation as biomarkers for high-grade cervical lesions.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26823825","citation_count":25,"is_preprint":false},{"pmid":"10834944","id":"PMC_10834944","title":"RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis.","date":"2000","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/10834944","citation_count":25,"is_preprint":false},{"pmid":"9822923","id":"PMC_9822923","title":"Reduced expression of retinoic acid receptor beta protein (RAR beta) in human papillary thyroid carcinoma: immunohistochemical and western blot study.","date":"1998","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/9822923","citation_count":24,"is_preprint":false},{"pmid":"18957410","id":"PMC_18957410","title":"Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18957410","citation_count":23,"is_preprint":false},{"pmid":"23851445","id":"PMC_23851445","title":"Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARβ signaling.","date":"2013","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/23851445","citation_count":23,"is_preprint":false},{"pmid":"21690307","id":"PMC_21690307","title":"RA-RAR-β counteracts myelin-dependent inhibition of neurite outgrowth via Lingo-1 repression.","date":"2011","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21690307","citation_count":22,"is_preprint":false},{"pmid":"30576962","id":"PMC_30576962","title":"Methylation status of SFRP1, SFRP2, RASSF1A, RARβ and DAPK1 genes in patients with oral squamous cell carcinoma.","date":"2018","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/30576962","citation_count":21,"is_preprint":false},{"pmid":"7556459","id":"PMC_7556459","title":"TGF-beta modulates the expression of retinoic acid-induced RAR-beta in primary cultures of embryonic palate cells.","date":"1995","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/7556459","citation_count":19,"is_preprint":false},{"pmid":"8835319","id":"PMC_8835319","title":"Altered distribution of the nuclear receptor RAR beta accompanies proliferation and differentiation changes caused by retinoic acid in Caco-2 cells.","date":"1996","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/8835319","citation_count":19,"is_preprint":false},{"pmid":"17438348","id":"PMC_17438348","title":"Immunohistochemical expression of RARalpha, RARbeta, and Cx43 in breast tumor cell lines after treatment with lycopene and correlation with RT-QPCR.","date":"2007","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/17438348","citation_count":18,"is_preprint":false},{"pmid":"29848550","id":"PMC_29848550","title":"Combinatorial knockout of RARα, RARβ, and RARγ completely abrogates transcriptional responses to retinoic acid in murine embryonic stem cells.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29848550","citation_count":18,"is_preprint":false},{"pmid":"25040980","id":"PMC_25040980","title":"Combined effects methylation of FHIT, RASSF1A and RARβ genes on non-small cell lung cancer in the Chinese population.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25040980","citation_count":18,"is_preprint":false},{"pmid":"34238300","id":"PMC_34238300","title":"LncRNA HAND2-AS1 exerts anti-oncogenic effects on bladder cancer via restoration of RARB as a sponge of microRNA-146.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34238300","citation_count":18,"is_preprint":false},{"pmid":"8528505","id":"PMC_8528505","title":"Antisense oligonucleotides to CRABP I and II alter the expression of TGF-beta 3, RAR-beta, and tenascin in primary cultures of embryonic palate cells.","date":"1995","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/8528505","citation_count":18,"is_preprint":false},{"pmid":"7958440","id":"PMC_7958440","title":"Reciprocal changes in Hox D13 and RAR-beta 2 expression in response to retinoic acid in chick limb buds.","date":"1994","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7958440","citation_count":18,"is_preprint":false},{"pmid":"33069074","id":"PMC_33069074","title":"Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review.","date":"2020","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33069074","citation_count":17,"is_preprint":false},{"pmid":"15766561","id":"PMC_15766561","title":"An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15766561","citation_count":17,"is_preprint":false},{"pmid":"12392082","id":"PMC_12392082","title":"Role of coactivators and corepressors in the induction of the RARbeta gene in human colon cancer cells.","date":"2002","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/12392082","citation_count":17,"is_preprint":false},{"pmid":"22992440","id":"PMC_22992440","title":"Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RARβ) and survivin genes in tumor tissues and voided urine of bladder cancer patients.","date":"2012","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/22992440","citation_count":17,"is_preprint":false},{"pmid":"15736225","id":"PMC_15736225","title":"Retinoid signaling competence and RARbeta-mediated gene regulation in the developing mammalian telencephalon.","date":"2005","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/15736225","citation_count":16,"is_preprint":false},{"pmid":"15610529","id":"PMC_15610529","title":"The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene.","date":"2004","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15610529","citation_count":16,"is_preprint":false},{"pmid":"10373014","id":"PMC_10373014","title":"RARbeta mediates the response of Hoxd4 and Hoxb4 to exogenous retinoic acid.","date":"1999","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/10373014","citation_count":16,"is_preprint":false},{"pmid":"11149416","id":"PMC_11149416","title":"Expression of RARalpha and RARbeta in human oral potentially malignant and neoplastic lesions.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11149416","citation_count":16,"is_preprint":false},{"pmid":"21822036","id":"PMC_21822036","title":"Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.","date":"2011","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/21822036","citation_count":16,"is_preprint":false},{"pmid":"12076325","id":"PMC_12076325","title":"The retinoic acid receptor-beta (RAR-beta) mRNA expression in the oral squamous cell carcinoma associated with betel quid use.","date":"2002","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12076325","citation_count":16,"is_preprint":false},{"pmid":"14970867","id":"PMC_14970867","title":"Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14970867","citation_count":16,"is_preprint":false},{"pmid":"17001699","id":"PMC_17001699","title":"Truncated RAR beta isoform enhances proliferation and retinoid resistance.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17001699","citation_count":15,"is_preprint":false},{"pmid":"22970018","id":"PMC_22970018","title":"Methylation of the RASSF1A and RARβ genes as a candidate biomarker for lung cancer.","date":"2012","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22970018","citation_count":15,"is_preprint":false},{"pmid":"25933005","id":"PMC_25933005","title":"An Unexpected Mode Of Binding Defines BMS948 as A Full Retinoic Acid Receptor β (RARβ, NR1B2) Selective Agonist.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25933005","citation_count":14,"is_preprint":false},{"pmid":"25997921","id":"PMC_25997921","title":"Retinoids induce cellular senescence in breast cancer cells by RAR-β dependent and independent pathways: Potential clinical implications (Review).","date":"2015","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25997921","citation_count":14,"is_preprint":false},{"pmid":"15010078","id":"PMC_15010078","title":"Differential expression of retinoic acid receptor beta (RARbeta) and the AP-1 transcription factor in normal, premalignant and malignant human laryngeal tissues.","date":"2004","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/15010078","citation_count":14,"is_preprint":false},{"pmid":"11697325","id":"PMC_11697325","title":"Enhanced apoptosis and radiosensitization by combined 13-cis-retinoic acid and interferon-alpha2a; role of RAR-beta gene.","date":"2001","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/11697325","citation_count":14,"is_preprint":false},{"pmid":"8606853","id":"PMC_8606853","title":"Postnatal rat lung retinoic acid receptor (RAR) mRNA expression and effects of dexamethasone on RAR beta mRNA.","date":"1995","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/8606853","citation_count":14,"is_preprint":false},{"pmid":"18629284","id":"PMC_18629284","title":"Methylation analysis of several tumour suppressor genes shows a low frequency of methylation of CDKN2A and RARB in uveal melanomas.","date":"2003","source":"Comparative and functional genomics","url":"https://pubmed.ncbi.nlm.nih.gov/18629284","citation_count":14,"is_preprint":false},{"pmid":"24796328","id":"PMC_24796328","title":"A meta-analysis of the relationship between RARβ gene promoter methylation and non-small cell lung cancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24796328","citation_count":13,"is_preprint":false},{"pmid":"34086186","id":"PMC_34086186","title":"MiR-141-3p and miR-200a-3p are involved in Th17 cell differentiation by negatively regulating RARB expression.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/34086186","citation_count":13,"is_preprint":false},{"pmid":"10652610","id":"PMC_10652610","title":"Retinoic acid modulates RAR alpha and RAR beta receptors in human glioma cell lines.","date":"1999","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10652610","citation_count":13,"is_preprint":false},{"pmid":"25605205","id":"PMC_25605205","title":"Association of methylation of the RAR-β gene with cigarette smoking in non-small cell lung cancer with Southern-Central Chinese population.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25605205","citation_count":13,"is_preprint":false},{"pmid":"32959699","id":"PMC_32959699","title":"All-Trans Retinoic Acid Rescues the Tumor Suppressive Role of RAR-β by Inhibiting LncHOXA10 Expression in Gastric Tumorigenesis.","date":"2020","source":"Nutrition and cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32959699","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54132,"output_tokens":10620,"usd":0.160848,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21868,"output_tokens":6692,"usd":0.13832,"stage2_stop_reason":"end_turn"},"total_usd":0.299168,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"Recombinant RARβ (full-length and ligand-binding domain expressed in COS1 cells and E. coli) binds retinoic acid with similar affinity to RARα; only retinoid analogues with an acidic end-group actively bind both receptors; two retinoid analogues showed preferential binding to either RARα or RARβ, demonstrating that RARβ has a distinct ligand-binding site.\",\n      \"method\": \"Radioligand binding assay using recombinant full-length receptors (COS1 expression) and bacterially expressed ligand-binding domains\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro binding assay with both full-length and truncated recombinant proteins, two expression systems, replicated across multiple ligands\",\n      \"pmids\": [\"2176462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The RARβ2 promoter contains a retinoic acid response element (RARE) that drives spatially and temporally restricted expression during mouse embryogenesis; promoter activity is selectively induced by teratogenic doses of RA in regions where malformations subsequently appear (craniofacial region, hindbrain, limbs), suggesting RARβ2 mediates some teratogenic effects of RA.\",\n      \"method\": \"Transgenic mice carrying RAR-β2 promoter–lacZ reporter gene; β-galactosidase expression mapping throughout embryogenesis; RA teratogen treatment in vivo\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple independent transgenic lines, in vivo reporter assay with RA treatment, replicated spatial pattern\",\n      \"pmids\": [\"1668276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"RARβ4, an isoform generated from the same retinoic acid-responsive P2 promoter as RARβ2 by alternative splicing, is initiated by a non-AUG (CUG) codon, has a very short A region (4 amino acids), exhibits a tissue-specific expression pattern, and has distinct transcriptional activation properties compared to other RARβ isoforms.\",\n      \"method\": \"cDNA cloning, sequencing, Northern blot for tissue expression, transient transfection transcriptional activation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — molecular cloning with sequencing, functional transcriptional assays, tissue expression characterization\",\n      \"pmids\": [\"1313565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"RARβ1/β3 transcripts are selectively expressed in embryonic CNS and their RA-induced accumulation occurs via a RA-dependent release of a block in RNA chain elongation (not transcriptional initiation), as distinct from RARβ2/β4 which are regulated at the level of transcriptional initiation via RARE.\",\n      \"method\": \"P1 promoter isolation, transgenic reporter animals, nuclear run-on transcription analysis in embryonal carcinoma cells\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — nuclear run-on assay directly measuring transcriptional elongation vs. initiation; validated in vivo with transgenic reporters\",\n      \"pmids\": [\"8011555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"RAR-β2 null mutant mice (targeted disruption) appear phenotypically normal, indicating other RARs compensate for RARβ2 during prenatal and postnatal development; challenging RARβ2-null embryos with teratogenic RA doses addressed whether RARβ2 is required for RA-induced malformations.\",\n      \"method\": \"Targeted gene disruption (knock-out mice), phenotypic and histological analysis, RA teratogen challenge\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with detailed phenotyping and RA challenge, published by Chambon lab\",\n      \"pmids\": [\"7958449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Overexpression of RARβ2 in RAR-γ-null F9 cells only poorly restores differentiation (though it can replace RARγ for activation of some target genes), revealing partial functional redundancy among RARs with isoform-specific limits.\",\n      \"method\": \"Stable transfection rescue cell lines in RAR-γ-null F9 embryonal carcinoma cells; gene expression and differentiation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — rescue experiment in null background, single lab, multiple target-gene readouts\",\n      \"pmids\": [\"7644503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Adenovirus E1A functions as a cofactor for RARβ by direct physical interaction: E1A interacts specifically with the hormone-dependent activation function (AF-2) of RARβ (but not AF-1 or AF-2 of RXRα), requiring conserved region III (CRIII) and the region around amino acid 178, thereby stabilizing the preinitiation complex and enabling RA-induced RARβ2 promoter activation.\",\n      \"method\": \"Co-immunoprecipitation, deletion mutagenesis of E1A, transient transfection transcriptional assays, GST pulldown\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding demonstrated with pulldown and Co-IP, deletion mapping of interacting domains, functional transcription assays confirming mechanistic role\",\n      \"pmids\": [\"7565739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"RARβ2 inhibits cell proliferation and anchorage-independent growth in HeLa cells: stable expression of RARβ2 results in >50% growth inhibition and reduced soft-agar colony formation, effects further enhanced by exogenous all-trans-retinoic acid.\",\n      \"method\": \"Stable transfection of RARβ2 in HeLa cells; cell proliferation assays; soft agar colony formation assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cellular phenotype with loss/gain of function, two orthogonal proliferation readouts, single lab\",\n      \"pmids\": [\"8635481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Translation of RARβ2 mRNA is regulated by upstream open reading frames (uORFs) in the 5'-UTR; uORF4 encodes a peptide whose amino acid sequence (not merely the act of translation) is critical for inhibiting translation of the downstream major ORF in heart and brain, while uORFs 2 and 5 are important for efficient translation in all tissues.\",\n      \"method\": \"Systematic site-directed mutagenesis of uORF start codons and coding sequences; transient expression with reporter constructs in multiple tissues\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis distinguishing peptide sequence vs. translational reinitiation, tested in multiple tissue contexts\",\n      \"pmids\": [\"8769409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Homozygous RARβ null mice are growth-deficient and display homeotic transformations of cervical vertebrae, a retrolenticular membrane, and persistence/hyperplasia of the primary vitreous body; RARα/RARβ double mutants have severe visceral abnormalities including agenesis of the stapedial artery, thymic and spleen agenesis, and abnormal inferior vena cava; RARβ/RARγ double mutants show major ocular defects including shortened ventral retina and prenatal retinal dysplasia.\",\n      \"method\": \"Homozygous and compound RAR knockout mouse phenotyping; histological and morphological analysis\",\n      \"journal\": \"The International journal of developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via compound knockout animals, comprehensive phenotypic analysis across multiple organ systems, replicated across labs\",\n      \"pmids\": [\"9240560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Stable expression of RARβ in RARβ-negative, trans-RA-resistant lung cancer cells (SK-MES-1 and H661) restores trans-RA-induced growth inhibition and apoptosis (at low serum concentration), demonstrating that RARβ expression is required for retinoid responsiveness in lung cancer cells.\",\n      \"method\": \"Stable transfection of RARβ in RARβ-negative lung cancer lines; cell growth assay; fluorescence microscopy and TdT apoptosis assay\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with specific phenotypic readout (growth inhibition and apoptosis), single lab, two orthogonal assays\",\n      \"pmids\": [\"9426695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Targeted disruption of both alleles of RARβ2 in F9 teratocarcinoma cells abolishes RA-induced growth arrest and impairs late differentiation responses (e.g., no induction of laminin B1), while early RA-responsive gene induction is markedly reduced; RA metabolism after differentiation is not impaired.\",\n      \"method\": \"Homologous recombination to generate RARβ2+/- and RARβ2-/- F9 cell lines; growth assays, morphological analysis, gene expression (early and late RA-responsive genes), RA metabolism assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — homologous recombination knockout in cell line with multiple orthogonal functional readouts, heterozygote controls, single rigorous study\",\n      \"pmids\": [\"10480883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RARβ mediates the response of Hoxd4 and Hoxb4 to exogenous RA: Rarb-null mice show only partial anteriorization of Hoxd4 and Hoxb4 expression in response to RA treatment; genetic analysis shows no synergistic interaction between Hoxd4 and Rarb in cervical vertebrae specification.\",\n      \"method\": \"Rarb-null mice treated with RA; in situ hybridization for Hoxd4 and Hoxb4; Hoxd4/Rarb double-mutant generation\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in knockout mice, in situ hybridization, single lab\",\n      \"pmids\": [\"10373014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RARβ2 transfection into RARβ-deficient lung tumor cells upregulates ICAM-1 and MHC class I expression (mRNA and cell surface protein), and enhances heterologous CTL responses up to threefold in both induction and effector phases, revealing a role for RARβ2 in regulating tumor cell immunogenicity.\",\n      \"method\": \"cDNA array (Atlas human cDNA array); flow cytometry for ICAM-1 and MHC class I protein; CTL response assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transfection gain-of-function with protein-level confirmation by flow cytometry and functional immune assay, single lab\",\n      \"pmids\": [\"10834944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Nicotine abrogates the growth inhibitory effect of trans-RA by suppressing RA-induced RARβ expression; this suppression is mediated by nicotine-induced orphan receptor TR3, which interacts with COUP-TF, inhibiting COUP-TF DNA binding and transactivation on the RARβ promoter; RXR-selective retinoid SR11237 activates the RARβ promoter through RXR/TR3 heterodimer and escapes nicotine suppression.\",\n      \"method\": \"Transient transfection promoter activity assays; TR3 antisense RNA overexpression; co-transfection of TR3 expression vector; cell growth assays\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection with promoter assays, antisense RNA, and co-transfection, single lab, multiple orthogonal experiments\",\n      \"pmids\": [\"11979430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The RA-insensitivity of RARβ induction in RA-resistant colon cancer cells (DLD-1) is associated with differential coactivator/corepressor balance: coactivators CBP and p300 upregulate RARβ RARE activity to levels seen in sensitive cells; corepressor NCoR suppresses RARE activity; HDAC inhibitor trichostatin A restores RARβ induction, implicating histone deacetylase in RARβ gene repression.\",\n      \"method\": \"Transfection of reporter constructs with RARβ promoter fragments; cotransfection of coactivators (CBP, p300) and corepressor (NCoR); Western blot for coregulator expression; HDAC inhibitor treatment\",\n      \"journal\": \"Biological & pharmaceutical bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter-reporter dissection with gain-of-function coregulator transfections and pharmacological inhibition, single lab\",\n      \"pmids\": [\"12392082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RARβ–RXRα heterodimers bound to the DR4 element in the thrombomodulin (TM) promoter are required for TM transcription: oxidized phospholipids from ox-LDL reduce nuclear RARβ and RXRα levels and their binding to the DR4 element, thereby inhibiting TM gene transcription in endothelial cells.\",\n      \"method\": \"EMSA (electrophoretic mobility shift assay); TM promoter deletion/mutation reporter assays in HUVEC transfection; Western blot for nuclear receptor levels; mRNA half-life (actinomycin D) analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA binding assay plus promoter deletion reporter functional assays, single lab, two orthogonal approaches\",\n      \"pmids\": [\"12576329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RARβ-selective agonist BMS453 induces fusion/hypoplasia of the first two branchial arches in cultured mouse embryos via RARβ/RXR heterodimers specifically in pharyngeal endoderm (not neural crest or ectoderm); effects are absent in Rarb-null embryos, enhanced by RXR agonists, and accompanied by ectopic RARβ target gene expression; RXR ligand-dependent activity is subordinated to RARβ in this heterodimer.\",\n      \"method\": \"Ex vivo cultured mouse embryo treatment with synthetic RAR-selective agonists/antagonists; genetic rescue using Rarb-null embryos; in situ hybridization for RARβ target genes; tissue-specific responsiveness assays\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological selectivity combined with genetic null rescue, multiple agonist/antagonist controls, tissue dissection experiments\",\n      \"pmids\": [\"12668623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A novel RARβ isoform, RARβ5, is expressed from a distinct P3 promoter activated by all-trans-RA; RARβ5 protein lacks the A, B, and part of C domains of RARβ2 (translation begins at an internal methionine); it is preferentially expressed in ER-negative breast cancer cells and may confer relative retinoid resistance.\",\n      \"method\": \"cDNA cloning and sequencing; promoter mapping; RT-PCR and Western blot across breast cancer cell lines; RA/retinoid treatment transcriptional assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — molecular characterization of novel isoform with sequencing and promoter mapping, Western blot, functional RA induction assay, single lab\",\n      \"pmids\": [\"15604252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RARβ mediates retinoid-driven striatal STEP (striatal-enriched tyrosine phosphatase) expression: RARβ-null mice show reduced STEP mRNA in the striatum, and ectopic RARβ1 expression in cerebral cortex enhances STEP expression in an RARβ-isoform-specific manner.\",\n      \"method\": \"RT-PCR in RARβ-/- mice; ectopic expression of RARβ1 by in utero electroporation; in situ hybridization and quantitative gene expression\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function knockout plus gain-of-function ectopic expression, isoform specificity tested, single lab\",\n      \"pmids\": [\"15736225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"At the RARβ2 RARE in F9 cells, RARγ and RXRα are constitutively bound; upon RA treatment, coactivators pCIP, p300, and RNA Pol II levels increase at the RARβ2 RARE; the polycomb protein SUZ12 is associated with the RARβ2 RARE and is evicted upon RA treatment (and reassociates upon RA removal); bivalent H3K4me2/H3K27me3 chromatin marks coexist at target loci, with H3K27me3 decreasing during RA-mediated differentiation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for RARγ, RXRα, pCIP, p300, RNA Pol II, SUZ12, and histone marks in F9 cells ± RA treatment\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP assays for multiple factors and histone marks at defined genomic loci, dynamic RA-dependent kinetics, rigorous controls\",\n      \"pmids\": [\"17663992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Rexinoid-induced IGFBP-6 expression requires RARβ-dependent cooperation between retinoid receptors and AP-1: a classical RARE in IGFBP-6 intron 1 adjacent to an AP-1 site is essential; bexarotene increases occupancy of this element by RXRα, RARβ, cJun, cFos, and p300; siRNA knockdown of RARβ (but not RARα or RARγ alone) blocks IGFBP-6 induction and prevents RXRα and cJun recruitment to the enhancer.\",\n      \"method\": \"Chromatin immunoprecipitation; siRNA knockdown of individual RAR/RXR isoforms; IGFBP-6 reporter assays; Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP plus isoform-specific siRNA knockdown plus reporter assays identifying both cis-elements and trans-factors, single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"18957410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RARβ activation stimulates Sonic hedgehog (Shh) signaling and induces proliferation of adult forebrain neural progenitor cells (NPCs); subsequent RARα signaling drives differentiation into Doublecortin-expressing migrating neuroblasts and cholinergic neurons; FGF signaling induces CYP26A1 expression and its product 4-oxo-RA mimics RARα agonist action in neuronal differentiation.\",\n      \"method\": \"In vivo and in vitro RARβ/RARα agonist treatment of adult forebrain NPCs; immunostaining for GFAP, DCX, cholinergic markers; pharmacological pathway dissection (Shh inhibitors, FGF treatment)\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with specific agonists, immunostaining cellular readouts, single lab\",\n      \"pmids\": [\"19100254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RA-RARβ transcriptionally represses Lingo-1 (a component of the NgR inhibitory complex), thereby counteracting myelin-dependent inhibition of neurite outgrowth; suppression of Lingo-1 is required for RARβ-mediated promotion of neurite outgrowth; in vivo RA treatment after dorsal column injury inhibits Lingo-1 expression specifically through RARβ.\",\n      \"method\": \"In vitro neurite outgrowth assays with RA/RARβ agonists on myelin substrates; Lingo-1 siRNA knockdown rescue; in vivo dorsal column overhemisection model with RA treatment; RARβ-null genetic controls\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function (Lingo-1 siRNA), pharmacological, and genetic (RARβ-null) evidence converging on a defined mechanism, in vitro and in vivo\",\n      \"pmids\": [\"21690307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RARβ regulates p14ARF levels in human melanocytes: ATRA treatment increases p14ARF expression via RARβ; an inverse correlation exists between RARB promoter hypermethylation and p14ARF (CDKN2A) alterations in melanoma cell lines; ATRA-induced senescence is reduced in p14ARF-depleted melanocytes, establishing a RARβ–p14ARF signaling axis.\",\n      \"method\": \"Mutual exclusivity analysis in 110 melanoma cell lines; ATRA treatment of primary melanocytes with p14ARF measurement; siRNA depletion of p14ARF; senescence assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — combination of correlational genomics with functional siRNA knockdown and pharmacological intervention, single lab\",\n      \"pmids\": [\"23851445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TLR3 activation by polyinosinic:polycytidylic acid induces microRNAs (miR-29b, -29c, -148b, -152) that target DNA methyltransferases, leading to demethylation and re-expression of epigenetically silenced RARβ; re-expressed RARβ renders prostate and breast cancer cells sensitive to retinoic acid-induced apoptosis in vitro and in vivo.\",\n      \"method\": \"miRNA expression profiling; luciferase reporter assays for miRNA-DNMT targeting; methylation-specific PCR for RARβ demethylation; apoptosis assays in vitro; in vivo tumor xenograft models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway from TLR3 → miRNAs → DNMT → RARβ demethylation established with multiple assays and in vivo validation, single lab\",\n      \"pmids\": [\"23716670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RARβ activation by a specific agonist in neurons decreases PTEN activity by cytoplasmic phosphorylation and increases PTEN secretion in exosomes; these PTEN-containing exosomes are taken up by astrocytes, hampering their proliferation and preventing glial scar formation; this dual mechanism results in axonal regeneration after dorsal root neurotmesis.\",\n      \"method\": \"RARβ agonist treatment in rat cervical avulsion model; BDA axonal tracing; exosome inhibitor in vivo and PTEN siRNA in vitro; phospho-PTEN Western blot; astrocyte proliferation assays\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection with pharmacological, siRNA, and exosome-inhibitor approaches, in vitro and in vivo, single lab\",\n      \"pmids\": [\"26609164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RARβ deletion impairs pancreatic endocrine differentiation: RARβ knockout embryonic stem cells show greatly reduced expression of glucagon, IAPP, and Ins1 during directed differentiation into pancreatic islet cells.\",\n      \"method\": \"RARβ knockout ES cell differentiation protocol; RT-PCR for endocrine markers\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined differentiation protocol and specific marker readouts, single lab\",\n      \"pmids\": [\"23756134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NR2F1-induced dormancy in disseminated tumor cells requires RARβ: NR2F1-dependent quiescence is dependent on SOX9, RARβ, and CDK inhibitors; this dormancy programme is recapitulated by co-treatment with 5-Aza-C and retinoic acid.\",\n      \"method\": \"shRNA knockdown of RARβ/SOX9 in experimental dormancy models; in vivo HNSCC and prostate cancer dormancy assays; flow cytometry for cell cycle arrest\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function knockdown in dormancy models in vitro and in vivo, epistasis placing RARβ downstream of NR2F1, single lab\",\n      \"pmids\": [\"25636082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RARβ activates CD38 transcription in hypothalamic neurons: ChIP assays show RA enhances binding of RARβ to the proximal promoter of CD38; adenoviral RARβ overexpression or siRNA knockdown bidirectionally modulates CD38 levels; RARβ activation increases neuronal Ca2+ excitability and OXT release; gestational vitamin A deficiency reduces hypothalamic RARβ and CD38, impairing oxytocin signaling.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); adenoviral RARβ overexpression and siRNA knockdown in primary hypothalamic neurons; Ca2+ imaging; serum oxytocin ELISA; rat gestational VAD model\",\n      \"journal\": \"Molecular nutrition & food research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP directly showing RARβ binding to CD38 promoter, bidirectional gain/loss of function, in vitro and in vivo, single lab\",\n      \"pmids\": [\"29266770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"De novo gain-of-function mutations in RARB (p.Gly296Ala and p.Leu213Pro) increase RA ligand-induced transcriptional activity 2- to 3-fold over wild-type receptor in transfection assays, consistent with previously reported p.Arg387Cys/Ser mutations; these mutations cause a syndrome of microphthalmia, diaphragmatic hernia, global developmental delay, and progressive motor impairment.\",\n      \"method\": \"Transient transfection transcriptional activation assays comparing wild-type vs. mutant RARB; clinical characterization of patients with de novo mutations\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct functional transcriptional assay with mutant constructs demonstrating gain-of-function, single lab\",\n      \"pmids\": [\"27120018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Genome-wide ChIP-seq of RARβ in mouse striatum combined with transcriptomics of RARβ-null mice identifies RARβ transcriptional targets enriched for neurotransmission, energy metabolism, and G-protein coupled receptor signaling (including cAMP and calcium pathways); RARβ is partially sequestered in huntingtin protein aggregates in R6/2 HD mice, reducing RA signaling in HD.\",\n      \"method\": \"ChIP-seq for RARβ in striatum; RNA-seq transcriptomics of RARβ-null mice; co-immunoprecipitation/immunofluorescence for RARβ-huntingtin co-localization in R6/2 mice\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genome-wide ChIP-seq plus knockout transcriptomics plus protein interaction in disease model, rigorous multi-omic approach, single lab\",\n      \"pmids\": [\"27405468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of multi-domain RARβ–RXRα heterodimer bound to DNA, ligands, and coactivator peptides reveals that the RARβ LBD and DBD are physically connected through domain-domain interactions, enabling allosteric signal transmission between them; RXR remains flexible with loosely organized domains while RARβ LBD forms direct contact with the DBD via a surface patch.\",\n      \"method\": \"X-ray crystallography; hydrogen-deuterium exchange mass spectrometry (HDX-MS); mutagenesis of domain-domain interface; functional transcriptional assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure at high resolution with HDX-MS allosteric evidence and mutagenesis validation in a single rigorous study\",\n      \"pmids\": [\"29021580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of the RARβ LBD in complex with the RARβ-selective full agonist BMS948 and related compounds BMS641 and BMS411 reveals that a 180° flip of the amide linker accounts for RARβ selectivity over RARα; this structural analysis explains how a single retinoid can be an RARα antagonist and an RARβ full agonist simultaneously, and defines structural basis of partial agonism.\",\n      \"method\": \"X-ray crystallography of RARβ LBD–ligand complexes; transcriptional activation assays for agonist/antagonist properties\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures of RARβ LBD with multiple ligands, functional assays confirming agonist/antagonist properties\",\n      \"pmids\": [\"25933005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TBL1XR1-RARB fusion protein (from translocation in RARA-negative APL) homodimerizes and acts as a dominant-negative repressor of the retinoic acid receptor pathway; it enhances replating capacity of mouse bone marrow cells and inhibits myeloid maturation of human cord blood cells, similarly to PML-RARA; APL with RARB translocation shows attenuated response to ATRA.\",\n      \"method\": \"Whole-genome sequencing; PCR and FISH for translocations; transduction of TBL1XR1-RARB into cell lines; reporter assays for RA pathway transcriptional activity; bone marrow replating assay; cord blood myeloid differentiation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — molecular characterization of fusion protein, in vitro functional assays (dimerization, transcription, differentiation), and in vivo bone marrow assay in single rigorous study\",\n      \"pmids\": [\"29921692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RARβ acts as both an upstream regulator and downstream effector of miR-22 in colon cancer cells: RA and HDAC inhibitors induce miR-22 via RARβ binding to a DR5 motif; miR-22 in turn reduces HDAC1, HDAC4, and SIRT1 (through chromatin remodeling of RARβ and NUR77 loci); this circuit leads to simultaneous induction of cytoplasmic RARβ and NUR77, causing apoptosis.\",\n      \"method\": \"ChIP for RARβ binding to DR5 at miR-22 locus; miR-22 target validation (HDAC1); luciferase reporter assays; Western blot for RARβ/NUR77/HDACs; xenograft tumor model with miR-22 inducers\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishing direct RARβ binding to DR5, functional circuit validation with multiple assays and in vivo model, single lab\",\n      \"pmids\": [\"30252536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Combinatorial CRISPR knockout of all three RARs (α, β, γ) in murine embryonic stem cells completely abrogates all transcriptional responses to RA, demonstrating that RARs are essential for every RA-regulated transcript; no RAR-independent RA signaling pathway operates in these cells.\",\n      \"method\": \"CRISPR-mediated biallelic frameshift mutations in RARα, RARβ, and RARγ; RNA-seq transcriptome analysis of triple-null vs. WT cells ± RA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genome-scale genetic proof using triple CRISPR knockout and RNA-seq, comprehensive and definitive single-study design\",\n      \"pmids\": [\"29848550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CCL28 signaling via CCR10 increases RARβ expression by reducing the interaction between RARα and HDAC1; elevated RARβ inhibits invasion, EMT (inducing E-cadherin, reducing nuclear β-catenin), and RANKL-driven osteoclastogenesis in oral squamous cell carcinoma; intraperitoneally administered CCL28 inhibits tumor growth and osteolysis in mouse models.\",\n      \"method\": \"Co-immunoprecipitation of RARα–HDAC1 interaction ± CCL28; Western blot and invasion assays; mouse calvaria and tibia OSCC models; IHC of tumor tissues for RARβ\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing mechanism of RARβ upregulation, in vitro functional assays, in vivo xenograft model, single lab\",\n      \"pmids\": [\"31487270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RARβ (NR1B2) overexpression inhibits and knockdown promotes KIRC cell invasion and metastasis in vitro and in vivo; mechanistic investigation indicates RARβ suppresses EMT through the LATS1/2-YAP pathway.\",\n      \"method\": \"Lentiviral stable overexpression and knockdown of NR1B2 in KIRC cell lines; migration/invasion assays; nude mouse xenograft metastasis model; Western blot for EMT markers and LATS1/2-YAP pathway components\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional loss/gain of function in vitro and in vivo with defined pathway readout (LATS1/2-YAP), single lab\",\n      \"pmids\": [\"31391070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RARβ mediates RA protection against LPS-induced ferroptosis in hepatocytes: knockdown of RARβ gene significantly diminishes RA's anti-ferroptotic protective effect; RAR agonist/antagonist experiments show RARβ (and RARγ) activation is required for RA inhibition of ferroptosis; the mechanism involves regulation of Nrf2/HO-1/GPX4 signaling.\",\n      \"method\": \"RARβ gene knockdown in hepatocytes; RAR subtype-selective agonists and antagonists; LPS/erastin/RSL3-induced ferroptosis models; Western blot for Nrf2/HO-1/GPX4; serum iron and RBC disorder measurements in mice\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with selective agonist/antagonist pharmacology, in vitro and in vivo, single lab\",\n      \"pmids\": [\"37302616\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RARβ is a ligand-activated nuclear receptor that forms heterodimers with RXRα (and heterodimerizes with TBL1XR1 as an oncogenic fusion) whose crystal structure reveals allosteric domain-domain communication between the LBD and DBD; it binds retinoic acid and selective synthetic agonists (e.g., BMS948) to drive transcription of target genes (including RARβ2 itself, CD38, IGFBP-6, and Hox genes) via RAREs, with transcriptional output modulated by coactivators (CBP/p300/pCIP), corepressors (NCoR/HDAC1/EZH2/SUZ12), upstream open reading frames that regulate translation, and post-transcriptional silencing by miR-146 and miR-106a; functionally, RARβ2 is required for RA-induced growth arrest, promotes apoptosis and tumor cell immunogenicity, represses Lingo-1 to enable axonal regeneration, activates Shh signaling in neural progenitor proliferation, regulates PTEN activity and exosomal transfer to prevent glial scarring, drives the RARβ–p14ARF axis to suppress melanoma, and controls pancreatic endocrine differentiation and CD38-oxytocin signaling in the hypothalamus, while gain-of-function mutations cause a neurodevelopmental syndrome and dominant-negative RARB fusions drive retinoic acid-resistant acute promyelocytic leukemia.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RARβ is a ligand-activated nuclear receptor that binds retinoic acid through a distinct ligand-binding site and functions as the obligatory transcriptional effector of retinoid signaling, where combinatorial CRISPR knockout of all three RARs abolishes every RA-regulated transcript [#0, #36]. It operates as a RARβ–RXRα heterodimer bound to retinoic acid response elements; a multi-domain crystal structure of the DNA-bound heterodimer shows the RARβ ligand-binding domain physically contacts the DNA-binding domain to relay allosteric signals, while companion structures with the selective agonist BMS948 explain RARβ-selective activation through a flip of the amide linker [#32, #33]. Transcription from the RA-responsive RARβ2 (P2) promoter is governed by a RARE and tuned by the coactivator/corepressor balance — CBP, p300, and pCIP promote activity while NCoR, HDAC1, and the polycomb factor SUZ12 with bivalent H3K27me3 chromatin enforce repression — and the receptor itself drives target genes including IGFBP-6, CD38, Hox genes, and STEP [#15, #20, #21, #29]. RARβ output is further layered by additional isoforms from distinct promoters (β2/β4 via P2, β1/β3 via P1 elongation control, β5 via P3) and by uORF-mediated translational control of its 5'-UTR [#2, #3, #8, #18]. Functionally, RARβ2 is required for RA-induced growth arrest and apoptosis and confers retinoid responsiveness in cancer cells [#10, #11], suppresses tumorigenesis via a RARβ–p14ARF senescence axis and restraint of EMT [#24, #38], enhances tumor immunogenicity [#13], and in the nervous system represses Lingo-1 to enable neurite outgrowth, modulates PTEN secretion to prevent glial scarring, and stimulates Shh-dependent neural progenitor proliferation [#22, #23, #26]. In vivo, RARβ-null mice show homeotic vertebral transformations and ocular defects with extensive redundancy among RARs [#9]. Gain-of-function de novo RARB mutations that increase ligand-induced transcriptional activity cause a syndrome of microphthalmia, diaphragmatic hernia, and developmental delay [#30], while a dominant-negative TBL1XR1-RARB fusion drives retinoic acid-resistant acute promyelocytic leukemia [#34].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established that RARβ is a genuine retinoic acid receptor with a ligand-binding site distinct from RARα, providing the basis for subtype-selective retinoid pharmacology.\",\n      \"evidence\": \"Radioligand binding with recombinant full-length receptors and bacterially expressed LBDs across multiple retinoid analogues\",\n      \"pmids\": [\"2176462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the structural determinants of subtype selectivity\", \"No information on heterodimer requirement for binding in vivo\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Showed the RARβ2 promoter carries a functional RARE driving spatially restricted RA-responsive expression in the embryo, linking RARβ to RA teratogenesis.\",\n      \"evidence\": \"Transgenic RARβ2 promoter–lacZ reporter mice with in vivo RA challenge\",\n      \"pmids\": [\"1668276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Correlative for teratogenic causation rather than proof\", \"Did not identify downstream effector genes\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Distinguished how RARβ isoforms are differentially regulated — β2/β4 at transcriptional initiation via RARE versus β1/β3 via release of an elongation block — revealing layered control of receptor abundance.\",\n      \"evidence\": \"P1/P2 promoter analysis, transgenic reporters, and nuclear run-on assays in embryonal carcinoma cells; isoform cloning\",\n      \"pmids\": [\"8011555\", \"1313565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Factors controlling the elongation block not identified\", \"Physiological role of isoform diversity unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Genetic knockout demonstrated extensive functional redundancy among RARs, showing single RARβ loss is largely compensated in development.\",\n      \"evidence\": \"Targeted disruption of RARβ in mice with phenotyping and RA teratogen challenge\",\n      \"pmids\": [\"7958449\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which RARs compensate at specific loci\", \"Subtle or adult phenotypes not fully captured\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined isoform-specific limits to RAR redundancy, as RARβ2 only poorly rescues differentiation in RARγ-null cells.\",\n      \"evidence\": \"Stable rescue transfection in RARγ-null F9 embryonal carcinoma cells with differentiation readouts\",\n      \"pmids\": [\"7644503\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell-line context\", \"Mechanistic basis of isoform specificity not defined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identified E1A as a direct AF-2-interacting cofactor of RARβ, providing early mechanistic detail on coactivator-like stabilization of the RARβ preinitiation complex.\",\n      \"evidence\": \"Co-IP, GST pulldown, E1A deletion mapping, and transcriptional reporter assays\",\n      \"pmids\": [\"7565739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Viral cofactor; endogenous equivalent not established here\", \"Structural basis of AF-2 contact undefined at the time\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Linked RARβ2 expression to tumor suppression by showing it inhibits proliferation and anchorage-independent growth, and uncovered uORF-based translational regulation of the receptor.\",\n      \"evidence\": \"Stable RARβ2 expression in HeLa with proliferation/soft-agar assays; systematic uORF mutagenesis with reporters across tissues\",\n      \"pmids\": [\"8635481\", \"8769409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Growth-arrest target genes not identified in these studies\", \"uORF regulation not tied to disease phenotypes\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated that RARβ expression is required and sufficient to restore retinoid-induced growth inhibition and apoptosis in RA-resistant lung cancer cells, establishing RARβ loss as a mechanism of retinoid resistance.\",\n      \"evidence\": \"Stable RARβ transfection in RARβ-negative lung cancer lines with growth and TdT apoptosis assays\",\n      \"pmids\": [\"9426695\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Apoptotic effector pathway not mapped\", \"Single lab, limited cell lines\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Cell-line knockout and mouse genetics defined RARβ2 as required for RA-induced growth arrest and late differentiation, and as the mediator of RA-dependent Hox anteriorization.\",\n      \"evidence\": \"Biallelic RARβ2 disruption in F9 cells with growth/differentiation readouts; Rarb-null mice with Hoxd4/Hoxb4 in situ hybridization\",\n      \"pmids\": [\"10480883\", \"10373014\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only partial Hox responses, indicating additional receptors\", \"Direct vs. indirect target distinction incomplete\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Compound RAR knockouts revealed genetic epistasis and organ-specific requirements (vertebral homeosis, ocular development) for RARβ in concert with RARα and RARγ.\",\n      \"evidence\": \"Single and compound RAR knockout mouse phenotyping with histology\",\n      \"pmids\": [\"9240560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets underlying each defect not resolved\", \"Combinatorial logic among RARs incompletely mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the coregulator basis of RARβ retinoid resistance — coactivator/corepressor balance and HDAC activity control RARβ promoter induction.\",\n      \"evidence\": \"Promoter-reporter assays with CBP/p300/NCoR cotransfection and TSA HDAC inhibition in colon cancer cells; TR3/COUP-TF dissection in lung cells\",\n      \"pmids\": [\"12392082\", \"11979430\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous occupancy not shown in these reporter studies\", \"Single lab per finding\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"ChIP at the RARβ2 RARE established the dynamic chromatin logic — constitutive RAR/RXR binding, RA-induced coactivator/Pol II recruitment, SUZ12 eviction, and resolution of bivalent histone marks.\",\n      \"evidence\": \"ChIP for RARγ, RXRα, pCIP, p300, Pol II, SUZ12 and histone marks in F9 cells ± RA\",\n      \"pmids\": [\"17663992\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RARβ self-occupancy versus RARγ at the locus not fully separated\", \"Kinetics of polycomb reassembly only partially defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified specific RARβ target genes and cofactor cooperativity, with RARβ uniquely required for rexinoid-induced IGFBP-6 via RARE–AP-1 crosstalk.\",\n      \"evidence\": \"ChIP, isoform-specific siRNA, and reporter assays mapping cis-elements and trans-factors (RXRα, cJun, cFos, p300)\",\n      \"pmids\": [\"18957410\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability of RARE–AP-1 cooperation to other targets unknown\", \"Single cell context\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed RARβ–RXR heterodimers act in defined tissues to control target gene expression in vivo and bind functional DR-type elements regulating non-developmental genes such as thrombomodulin.\",\n      \"evidence\": \"Ex vivo embryo culture with RARβ-selective agonists and Rarb-null rescue; EMSA and promoter reporters at the thrombomodulin DR4 in endothelial cells\",\n      \"pmids\": [\"12668623\", \"12576329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RARβ occupancy at endogenous TM promoter not shown by ChIP\", \"Tissue-specific cofactor requirements unmapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Expanded RARβ tumor-suppressive mechanisms — a RARβ–p14ARF senescence axis, RARβ re-expression upon DNMT-targeting miRNAs restoring RA-induced apoptosis, and roles in immunogenicity, dormancy, and endocrine/neuronal differentiation.\",\n      \"evidence\": \"ATRA/siRNA p14ARF senescence assays in melanocytes; TLR3→miRNA→DNMT→RARβ demethylation with xenografts; NR2F1 dormancy knockdown; cDNA array/flow CTL assays; ES-cell pancreatic differentiation\",\n      \"pmids\": [\"23851445\", \"23716670\", \"25636082\", \"10834944\", \"23756134\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Many findings are single-lab and context-specific\", \"Direct RARβ target genes in these settings not always defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established RARβ as a driver of CNS repair by transcriptionally repressing Lingo-1, decreasing PTEN activity/exosomal export, and promoting Shh-dependent neural progenitor proliferation.\",\n      \"evidence\": \"Neurite outgrowth assays, Lingo-1 siRNA rescue, dorsal column injury and avulsion models with RARβ-null controls, exosome inhibition, pharmacological pathway dissection\",\n      \"pmids\": [\"21690307\", \"19100254\", \"26609164\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Lingo-1 and PTEN are direct RARβ targets not fully resolved\", \"Translation to therapeutic settings untested in these studies\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Solved the structural basis of RARβ subtype-selective ligand recognition, explaining how single compounds act as RARβ agonists while antagonizing RARα.\",\n      \"evidence\": \"X-ray crystallography of RARβ LBD with BMS948/BMS641/BMS411 plus transcriptional assays\",\n      \"pmids\": [\"25933005\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isolated LBD; full-length context addressed separately\", \"In vivo selectivity consequences not tested here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined RARβ's genome-wide neuronal target program and a CD38–oxytocin regulatory pathway, and linked RARβ sequestration in huntingtin aggregates to impaired RA signaling in disease.\",\n      \"evidence\": \"ChIP-seq of striatal RARβ with RARβ-null RNA-seq; ChIP and bidirectional manipulation at the CD38 promoter with Ca2+ imaging and oxytocin ELISA; Co-IP/IF in R6/2 HD mice\",\n      \"pmids\": [\"27405468\", \"29266770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional validation of most genome-wide targets pending\", \"Causal contribution of RARβ sequestration to HD phenotype not isolated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established that gain-of-function RARB mutations causing increased ligand-induced transcription underlie a defined neurodevelopmental syndrome, providing direct human disease evidence.\",\n      \"evidence\": \"Transcriptional activation assays of mutant versus wild-type RARB with clinical characterization of de novo mutation carriers\",\n      \"pmids\": [\"27120018\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specific consequences of hyperactivity not modeled\", \"Genotype–phenotype mapping limited to a few mutations\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed the integrated architecture of the DNA-bound RARβ–RXRα heterodimer, showing LBD–DBD allosteric coupling that links ligand binding to DNA engagement.\",\n      \"evidence\": \"Multi-domain X-ray crystallography with HDX-MS, interface mutagenesis, and transcriptional assays\",\n      \"pmids\": [\"29021580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics in the presence of full coactivator complexes not captured\", \"Chromatin context not represented in the crystal\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided definitive genetic proof that RARs (including RARβ) are obligatory for all RA transcriptional responses, and identified a dominant-negative TBL1XR1-RARB fusion driving RA-resistant APL.\",\n      \"evidence\": \"Triple RAR CRISPR knockout with RNA-seq; characterization of TBL1XR1-RARB dimerization, transcriptional repression, replating, and differentiation assays\",\n      \"pmids\": [\"29848550\", \"29921692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Triple-null result is in ES cells; tissue generalization assumed\", \"Fusion partner contribution to oncogenicity not fully dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended RARβ's anti-tumor role to invasion/EMT control via LATS1/2-YAP and CCL28/CCR10-driven RARβ upregulation, and to metabolic/redox protection against ferroptosis.\",\n      \"evidence\": \"Bidirectional NR1B2 manipulation with LATS1/2-YAP readouts in KIRC; RARα–HDAC1 Co-IP and OSCC models; RARβ knockdown with agonist/antagonist ferroptosis assays and Nrf2/HO-1/GPX4 analysis\",\n      \"pmids\": [\"31391070\", \"31487270\", \"37302616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RARβ transcriptional targets in these pathways not mapped\", \"Single-lab, context-specific findings\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RARβ's diverse target programs and tissue-specific cofactor/chromatin states are selected across contexts — and how gain-of-function and dominant-negative alleles produce their specific disease phenotypes mechanistically — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking isoform/promoter usage to context-specific output\", \"Mechanistic basis of mutant phenotypes at the tissue level undefined\", \"Direct versus indirect status of many proposed targets unconfirmed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [20, 21, 29, 31, 36]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [16, 21, 32]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [0, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [16, 20, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [20, 21, 29, 36]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9, 17, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [30, 34]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 11, 35]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"complexes\": [\n      \"RARβ–RXRα heterodimer\"\n    ],\n    \"partners\": [\n      \"RXRA\",\n      \"NCOR1\",\n      \"CREBBP\",\n      \"EP300\",\n      \"SUZ12\",\n      \"TBL1XR1\",\n      \"HTT\",\n      \"HDAC1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}